{"matching_results": 21749, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1366, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1062}, {"key": "negative", "matching_results": 302}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "watchlistnews.com", "matching_results": 723, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 559}, {"key": "negative", "matching_results": 164}]}]}, {"key": "thelincolnianonline.com", "matching_results": 713, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 534}, {"key": "negative", "matching_results": 179}]}]}, {"key": "wkrb13.com", "matching_results": 708, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 572}, {"key": "negative", "matching_results": 136}]}]}, {"key": "freelancer.com.co", "matching_results": 707, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 655}, {"key": "negative", "matching_results": 50}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "tickerreport.com", "matching_results": 671, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 582}, {"key": "negative", "matching_results": 88}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "dailypolitical.com", "matching_results": 584, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 492}, {"key": "negative", "matching_results": 92}]}]}, {"key": "zolmax.com", "matching_results": 516, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 386}, {"key": "negative", "matching_results": 129}]}]}, {"key": "theolympiareport.com", "matching_results": 470, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 358}, {"key": "negative", "matching_results": 111}]}]}, {"key": "reed.co.uk", "matching_results": 342, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 337}, {"key": "negative", "matching_results": 5}]}]}]}], "results": [{"id": "0BIEUUr4DR95V6Tf0IdmPcXku5Rb2Kouki-dJ0QOhaxdeISfVRxBX5h1QL4DT3N3", "result_metadata": {"score": 36.919514}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.881087, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.779571, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.944017, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.892905, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858826, "count": 1}]}, "crawl_date": "2018-11-23T21:37:38Z", "url": "http://www.4-traders.com/LONDON-STOCK-EXCHANGE-4005918/news/Norges-Bank-Form-8-3-Takeda-Pharmaceutical-Co-Ltd-27653813/", "host": "4-traders.com", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T00:00:00+01:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.608155, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.555262, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.536047, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.533632, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.518838, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501226, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.492581, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.466276, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.466276, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.466276, "type": "Quantity"}], "sentiment": {"document": {"score": 0.521202, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "for each offeror/offeree Takeda Pharmaceutical Co Ltd", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "with an offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "connect", "tense": "past"}, "text": "connected", "normalized": "connect"}}, {"subject": {"text": "a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}, {"text": "exempt fund manager"}, {"text": "separate form"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "identity of offeror/offeree: N/A (e) Date position held/dealing", "keywords": [{"text": "Date position held/dealing"}, {"text": "N/A"}, {"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "22/11/2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 22/11/2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d Yes", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " Class of relevant security: Ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 6,866,558 0.86 (2) Cash-settled derivatives: 2,551,000 0.32 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "9,417,558 1.18 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " TOTAL: 9,417,558 1.18 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "e.g. call option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 23/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 23/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "+4724073297 Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Date of disclosure: 23/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.981827, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.548286, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.527925, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.520802, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.470832, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.441937, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.425689, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.413626, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.389835, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option contract", "relevance": 0.373672, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Unit type", "relevance": 0.372284, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Security", "relevance": 0.362898, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Derivative", "relevance": 0.362135, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.360482, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.360337, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Moneyness", "relevance": 0.338976, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.946628, "label": "/real estate/buying and selling homes"}, {"score": 0.866992, "label": "/finance/financial news"}, {"score": 0.714907, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Sale 131,000 JPY 4,274.8411 Ordinary Sale 10,000 JPY 4,274.8411 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.726237, "arguments": [{"text": "i", "location": [3179, 3180], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3182, 3189], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3779, 3784], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3789, 3793], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4153, 4159], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4170, 4177], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 23/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5048, 5054], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5062, 5066], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5209, 5233], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5201, 5206], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5368, 5373], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5387, 5414], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.805113, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.668779, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.665301, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.650291, "count": 3}, {"text": "Full name of discloser", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.627334, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614088, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.592545, "count": 2}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573467, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.570521, "count": 3}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.568145, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561446, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556431, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549803, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.548305, "count": 1}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.546052, "count": 1}, {"text": "options", "sentiment": {"score": 0.380708, "mixed": "1", "label": "positive"}, "relevance": 0.545517, "count": 4}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.544688, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.544688, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.54232, "count": 2}, {"text": "naming of nominee", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.540224, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.539809, "count": 1}, {"text": "Code", "sentiment": {"score": -0.438402, "mixed": "1", "label": "negative"}, "relevance": 0.539281, "count": 3}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539136, "count": 1}, {"text": "subscription", "sentiment": {"score": 0.684266, "label": "positive"}, "relevance": 0.538563, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.537773, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.537486, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.537422, "count": 2}, {"text": "unit", "sentiment": {"score": 0.479402, "mixed": "1", "label": "positive"}, "relevance": 0.537125, "count": 5}, {"text": "relation", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.535485, "count": 3}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.534315, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.569891, "label": "positive"}, "relevance": 0.533881, "count": 2}, {"text": "offeree", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.533578, "count": 6}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530984, "count": 2}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530966, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529595, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.529595, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527476, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.52624, "count": 3}, {"text": "sale Number of securities Price", "sentiment": {"score": 0.857008, "label": "positive"}, "relevance": 0.525995, "count": 1}, {"text": "Takeover Panel", "sentiment": {"score": -0.737844, "label": "negative"}, "relevance": 0.525899, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.525738, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.857008, "label": "positive"}, "relevance": 0.52523, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525017, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.524974, "count": 2}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524844, "count": 2}, {"text": "Philippe Chiaroni Telephone number", "sentiment": {"score": -0.737844, "label": "negative"}, "relevance": 0.524701, "count": 1}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.524476, "count": 3}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523215, "count": 1}, {"text": "understandings", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.522918, "count": 3}, {"text": "Rule", "sentiment": {"score": -0.737844, "label": "negative"}, "relevance": 0.521695, "count": 1}]}, "extracted_metadata": {"sha1": "a032b54d9d9162b0724de2719526c1003c31141a", "filename": "1543009058583.zip-ffc3cd89d19a5d6da31294d9cb4d067f.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "Norges Bank : - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "Markets : News, Sectors, Financials - Marketscreener.com"}, {"id": "PqA3r3PGnl85g7TpQf87hFefCLDyvu3sJSItz6uGOYUpNMuE-h-7mMxQFPk-Nk9D", "result_metadata": {"score": 36.780407}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.881087, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.779571, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.931092, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.928689, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.877165, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.133886, "count": 1}]}, "crawl_date": "2018-11-23T16:00:55Z", "url": "https://www.marketscreener.com/LONDON-STOCK-EXCHANGE-4005918/news/Norges-Bank-Form-8-3-Takeda-Pharmaceutical-Co-Ltd-27653813/", "host": "marketscreener.com", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T00:00:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.608155, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.555262, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.536047, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.533632, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.518838, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501226, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.492581, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.466276, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.466276, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.466276, "type": "Quantity"}], "sentiment": {"document": {"score": 0.521202, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "for each offeror/offeree Takeda Pharmaceutical Co Ltd", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "with an offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "connect", "tense": "past"}, "text": "connected", "normalized": "connect"}}, {"subject": {"text": "a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager", "keywords": [{"text": "offeror/offeree Takeda Pharmaceutical"}, {"text": "exempt fund manager"}, {"text": "separate form"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}, {"type": "JobTitle", "text": "fund manager"}]}, "sentence": " Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken:", "object": {"text": "identity of offeror/offeree: N/A (e) Date position held/dealing", "keywords": [{"text": "Date position held/dealing"}, {"text": "N/A"}, {"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "22/11/2018 (f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " 22/11/2018 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d Yes", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " Class of relevant security: Ordinary Interests Short positions Number % Number % (1) Relevant securities owned and/or controlled: 6,866,558 0.86 (2) Cash-settled derivatives: 2,551,000 0.32 (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "9,417,558 1.18 All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " TOTAL: 9,417,558 1.18 All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "Exercising/", "keywords": [{"text": "Exercising/"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "e.g. call option", "keywords": [{"text": "option"}]}, "action": {"verb": {"text": "exercise", "tense": "past"}, "text": "exercised", "normalized": "exercise"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 23/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "made to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "+4724073297 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " Date of disclosure: 23/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "+4724073297 Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Date of disclosure: 23/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.981827, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.548286, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.527925, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.520802, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.470832, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.441937, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.425689, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.413626, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.389835, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Option contract", "relevance": 0.373672, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Unit type", "relevance": 0.372284, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Security", "relevance": 0.362898, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Derivative", "relevance": 0.362135, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.360482, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.360337, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Moneyness", "relevance": 0.338976, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}], "categories": [{"score": 0.946628, "label": "/real estate/buying and selling homes"}, {"score": 0.866992, "label": "/finance/financial news"}, {"score": 0.714907, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Sale 131,000 JPY 4,274.8411 Ordinary Sale 10,000 JPY 4,274.8411 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.726237, "arguments": [{"text": "i", "location": [3179, 3180], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3182, 3189], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3779, 3784], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3789, 3793], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4153, 4159], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4170, 4177], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 23/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5048, 5054], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5062, 5066], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5209, 5233], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5201, 5206], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5368, 5373], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5387, 5414], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.805113, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.668779, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.665301, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.650291, "count": 3}, {"text": "Full name of discloser", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.627334, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614088, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.592545, "count": 2}, {"text": "Short positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573467, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.570521, "count": 3}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.568145, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561446, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556431, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549803, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.548305, "count": 1}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.546052, "count": 1}, {"text": "options", "sentiment": {"score": 0.380708, "mixed": "1", "label": "positive"}, "relevance": 0.545517, "count": 4}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.544688, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.544688, "count": 1}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.54232, "count": 2}, {"text": "naming of nominee", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.540224, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.539809, "count": 1}, {"text": "Code", "sentiment": {"score": -0.438402, "mixed": "1", "label": "negative"}, "relevance": 0.539281, "count": 3}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539136, "count": 1}, {"text": "subscription", "sentiment": {"score": 0.684266, "label": "positive"}, "relevance": 0.538563, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.537773, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.537486, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.537422, "count": 2}, {"text": "unit", "sentiment": {"score": 0.479402, "mixed": "1", "label": "positive"}, "relevance": 0.537125, "count": 5}, {"text": "relation", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.535485, "count": 3}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.534315, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.569891, "label": "positive"}, "relevance": 0.533881, "count": 2}, {"text": "offeree", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.533578, "count": 6}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530984, "count": 2}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530966, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529595, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.529595, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527476, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.52624, "count": 3}, {"text": "sale Number of securities Price", "sentiment": {"score": 0.857008, "label": "positive"}, "relevance": 0.525995, "count": 1}, {"text": "Takeover Panel", "sentiment": {"score": -0.737844, "label": "negative"}, "relevance": 0.525899, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.525738, "count": 1}, {"text": "Purchases", "sentiment": {"score": 0.857008, "label": "positive"}, "relevance": 0.52523, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525017, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.524974, "count": 2}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524844, "count": 2}, {"text": "Philippe Chiaroni Telephone number", "sentiment": {"score": -0.737844, "label": "negative"}, "relevance": 0.524701, "count": 1}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.524476, "count": 3}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523215, "count": 1}, {"text": "understandings", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.522918, "count": 3}, {"text": "Rule", "sentiment": {"score": -0.737844, "label": "negative"}, "relevance": 0.521695, "count": 1}]}, "extracted_metadata": {"sha1": "49fed4e0f13a5f1a54968f95fe7f2963ac77a93b", "filename": "1542988855937.zip-480802c21e472c9d3ad0c961ffe77d29.xml", "file_type": "json"}, "external_links": ["http://www.thetakeoverpanel.org.uk/"], "title": "Norges Bank : - Form 8.3 - Takeda Pharmaceutical Co Ltd | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "3AnxKBIkRCiPb_LTYbKFugJaSduvdJhej9SQg2cfEoySVe4rpRIxwqhz-B1u2XJy", "result_metadata": {"score": 36.33243}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.881087, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.779571, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.944017, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.892905, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858826, "count": 1}]}, "crawl_date": "2018-11-23T15:46:46Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45356375-norges-bank-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T15:40:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.957808, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.923955, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "YesShire PLC", "relevance": 0.788874, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.7562, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.680231, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.680231, "type": "Quantity"}], "sentiment": {"document": {"score": -0.414576, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2.", "object": {"text": "a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2", "keywords": [{"text": "possible cash offer"}, {"text": "YesShire PLC"}, {"text": "N/A"}], "entities": [{"type": "Company", "text": "YesShire PLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945508, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.824762, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.672196, "dbpedia_resource": "http://dbpedia.org/resource/Security"}], "categories": [{"score": 0.807281, "label": "/real estate/buying and selling homes"}, {"score": 0.764456, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.755369, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.848095, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.690763, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.645889, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.637949, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.632136, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.630513, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612733, "count": 1}, {"text": "offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597277, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.740284, "label": "negative"}, "relevance": 0.593487, "count": 2}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576877, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573881, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.567425, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567354, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.566652, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564249, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563963, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561202, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555905, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.554905, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.5512, "count": 5}, {"text": "PERSON", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.551043, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.548087, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547646, "count": 2}, {"text": "Interests", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.544582, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54326, "count": 1}, {"text": "disclosure Dealing Disclosure22/11/2018", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540502, "count": 1}, {"text": "Bank", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.538759, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.537861, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536018, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532656, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.528078, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526358, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525723, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525613, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523425, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.522381, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517507, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512816, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512633, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.512321, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511421, "count": 1}, {"text": "Code", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.509187, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.499031, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.497197, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496333, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492573, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.48565, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.481823, "count": 1}, {"text": "vehicle companies", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.478283, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.470896, "count": 1}]}, "extracted_metadata": {"sha1": "414408a90a288db5e972f9b32a678ce2b1fb3bd6", "filename": "1542988006462.zip-ad286dfef407ca32ad4a40c722f022e1.xml", "file_type": "json"}, "title": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: News"}, {"id": "fFa_dJ0afJnkJ6IbyBbzxbRcsWozxaDGkPW2ZtmTAy-v5TNzVf6EdyNHZkO5pyrM", "result_metadata": {"score": 32.609554}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.60941, "label": "/business and industrial/company/merger and acquisition"}, {"score": 0.583102, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.547458, "label": "/business and industrial/business news"}], "relations": [], "keywords": [{"text": "Shire PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5, "count": 1}]}, "crawl_date": "2018-11-23T15:54:26Z", "url": "http://www.euroinvestor.com/news/2018/11/23/form-83-shire-plc/13934232", "host": "euroinvestor.com", "text": "If it is a cash offer or possible cash offer, state \u201cN/A\u201d Yes Takeda Pharmaceutical Co Ltd 2.", "country": "NO", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T15:23:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.85199, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.302655, "label": "negative"}, "text": "Norges Bank", "relevance": 0.830364, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.784253, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.705182, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.616036, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.616036, "type": "Quantity"}], "sentiment": {"document": {"score": 0.333897, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945465, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.82079, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.671779, "dbpedia_resource": "http://dbpedia.org/resource/Security"}], "categories": [{"score": 0.806785, "label": "/real estate/buying and selling homes"}, {"score": 0.75775, "label": "/finance/financial news"}, {"score": 0.756744, "label": "/finance/investing/funds/mutual funds"}], "relations": [], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.292821, "label": "negative"}, "relevance": 0.860314, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.669515, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.292821, "label": "negative"}, "relevance": 0.641016, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0.796282, "label": "positive"}, "relevance": 0.635578, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.632406, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.292821, "label": "negative"}, "relevance": 0.604362, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601934, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.740284, "label": "negative"}, "relevance": 0.596265, "count": 2}, {"text": "offer", "sentiment": {"score": 0.796282, "label": "positive"}, "relevance": 0.596048, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.591074, "count": 2}, {"text": "Owner", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.588743, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.292821, "label": "negative"}, "relevance": 0.585622, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585209, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0.796282, "label": "positive"}, "relevance": 0.577225, "count": 1}, {"text": "Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573153, "count": 1}, {"text": "PERSON", "sentiment": {"score": -0.292821, "label": "negative"}, "relevance": 0.572706, "count": 1}, {"text": "state", "sentiment": {"score": 0.796282, "label": "positive"}, "relevance": 0.569736, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56374, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561095, "count": 1}, {"text": "Interests", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.557395, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.55645, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552825, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.552436, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550464, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549098, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.547246, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546378, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532987, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.531832, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.530815, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52619, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.525617, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525411, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52446, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522457, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521537, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.292821, "label": "negative"}, "relevance": 0.519936, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519919, "count": 1}, {"text": "Code", "sentiment": {"score": -0.292821, "label": "negative"}, "relevance": 0.514866, "count": 1}, {"text": "Bank", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.513287, "count": 1}, {"text": "vehicle companies", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.510099, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0.846956, "label": "positive"}, "relevance": 0.509155, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508893, "count": 2}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.504603, "count": 5}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.498107, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.497529, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.488624, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.469056, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.459877, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.454991, "count": 1}]}, "extracted_metadata": {"sha1": "c3c749ee768991dfe93242420170f5deaabf0336", "filename": "1542988466900.zip-728e7706cc3878abd1462f5a57712672.xml", "file_type": "json"}, "external_links": ["http://www.facebook.com/2008/fbml"], "title": "Form 8.3 Shire PLC", "forum_title": "Euroinvestor.com A/S"}, {"id": "c2_gCIUksjHnHYGNljMUGINFeuZpeRPcLHk49ZdDoC_xwetDTLqAZh81S8xTR5lF", "result_metadata": {"score": 31.994785}, "author": "businesswire.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS PLC", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Barclays", "relevance": 0.972986, "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}, {"text": "United Kingdom", "relevance": 0.700474, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.5607, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.904926, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "PLC UK Regulatory Announcement", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.960803, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.769699, "count": 1}, {"text": "TAKEDA PHARMACEUTICAL CO LTD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.344607, "count": 1}]}, "crawl_date": "2018-11-23T16:15:11Z", "url": "https://www.businesswire.com/news/home/20181123005123/en/BARCLAYS-PLC-UK-Regulatory-Announcement-Form-8.3", "host": "businesswire.com", "text": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC. are being disclosed: Name of offeror/offeree in relation to whose TAKEDA PHARMACEUTICAL CO LTD relevant securities this from relates: 2.", "main_image_url": "http://www.businesswire.com/images/bwlogo_square.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T12:27:00-06:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Barclays PLC.", "relevance": 0.738032, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "TAKEDA PHARMACEUTICAL CO LTD", "relevance": 0.705632, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "SHIRE PLC", "relevance": 0.573144, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": -0.373848, "label": "negative"}, "text": "Class of Product Nature", "relevance": 0.563084, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "BARCLAYS", "relevance": 0.547137, "type": "Company", "disambiguation": {"subtype": [], "name": "Barclays", "dbpedia_resource": "http://dbpedia.org/resource/Barclays"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "LONDON", "relevance": 0.542674, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Contacts BARCLAYS PLC", "relevance": 0.519919, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.512274, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Large Holdings Regulatory Operations", "relevance": 0.467322, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.451296, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,365,800 1.30%", "relevance": 0.451296, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,521,600 1.32%", "relevance": 0.451296, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "10,941,600 1.38%", "relevance": 0.451296, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "11,131,864 1.40%", "relevance": 0.451296, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,629,586 1.59%", "relevance": 0.451296, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "12,859,395 1.62%", "relevance": 0.451296, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34,166,795 4.30%", "relevance": 0.451296, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "34,283,050 4.31%", "relevance": 0.451296, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.451296, "type": "Quantity"}], "sentiment": {"document": {"score": 0.633467, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "POSITIONS OF THE PERSON", "keywords": [{"text": "POSITIONS"}, {"text": "PERSON"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 34,283,050 4.31% 34,166,795 4.30% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "agreements"}, {"text": "options"}, {"text": "TOTAL"}], "entities": [{"type": "Quantity", "text": "10,521,600 1.32"}, {"type": "Quantity", "text": "10,941,600 1.38"}, {"type": "Quantity", "text": "34,166,795 4.30"}, {"type": "Quantity", "text": "34,283,050 4.31"}]}, "sentence": " Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,131,864 1.40% 12,859,395 1.62% (2) Cash-settled derivatives: 12,629,586 1.59% 10,365,800 1.30% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 34,283,050 4.31% 34,166,795 4.30% All interests and all short positions should be disclosed.", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "34,283,050 4.31% 34,166,795 4.30% All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}], "entities": [{"type": "Quantity", "text": "34,166,795 4.30"}, {"type": "Quantity", "text": "34,283,050 4.31"}]}, "sentence": " Ordinary NPV Interests Short Positions Number (%) Number (%) (1) Relevant securities owned and/or controlled: 11,131,864 1.40% 12,859,395 1.62% (2) Cash-settled derivatives: 12,629,586 1.59% 10,365,800 1.30% (3) Stock-settled derivatives (including options) and agreements to purchase/sell: 10,521,600 1.32% 10,941,600 1.38% (4) TOTAL: 34,283,050 4.31% 34,166,795 4.30% All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3.", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Expiry date Option money paid/ received per unit (ii) Exercise", "object": {"text": "Expiry date Option money", "keywords": [{"text": "Expiry date Option"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "subscribing for new securities", "keywords": [{"text": "new securities"}]}, "sentence": " Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "object": {"text": "Other dealings", "keywords": [{"text": "dealings"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "Class of relevant security Nature", "keywords": [{"text": "relevant security Nature"}, {"text": "Class"}]}, "sentence": " Class of relevant security Nature of dealing e.g. subscription, conversion", "object": {"text": "e.g. subscription, conversion", "keywords": [{"text": "e.g. subscription"}, {"text": "conversion"}]}, "action": {"verb": {"text": "deal", "tense": "future"}, "text": "dealing", "normalized": "deal"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "Irrevocable commitments and letters of intent", "keywords": [{"text": "Irrevocable commitments"}, {"text": "intent"}, {"text": "letters"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "object": {"text": "Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities", "keywords": [{"text": "option arrangement"}, {"text": "relevant securities"}, {"text": "indemnity"}, {"text": "agreement"}]}, "action": {"verb": {"text": "include", "tense": "future", "negated": true}, "text": "included", "normalized": "include"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any other person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or", "object": {"text": "to: (i) the voting rights of any relevant securities under any option", "keywords": [{"text": "voting rights"}, {"text": "relevant securities"}, {"text": "option"}], "entities": []}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "020 3134 7213 Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Public disclosures"}, {"text": "Rule"}, {"text": "Code"}]}, "sentence": " YES Date of disclosure: 23 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "details", "keywords": [{"text": "details"}]}, "sentence": " Full details should be given so that the nature of the interest or position can be fully understood: It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.", "object": {"text": "on a Supplemental Form (Open Positions)", "keywords": [{"text": "Supplemental Form"}, {"text": "Open Positions"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Receipt", "keywords": [{"text": "Receipt"}]}, "sentence": " Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659895 Time of Receipt (offset from UTC): 20181123T114352+0000 Contacts BARCLAYS PLC", "object": {"text": "from UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "offset", "tense": "past"}, "text": "offset", "normalized": "offset"}}], "concepts": [{"text": "Option", "relevance": 0.965064, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.753097, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.687385, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Put option", "relevance": 0.600447, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock", "relevance": 0.552667, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Derivative", "relevance": 0.423921, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Option style", "relevance": 0.417228, "dbpedia_resource": "http://dbpedia.org/resource/Option_style"}, {"text": "Options", "relevance": 0.380491, "dbpedia_resource": "http://dbpedia.org/resource/Options"}, {"text": "Moneyness", "relevance": 0.375827, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Security", "relevance": 0.344127, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "December", "relevance": 0.322198, "dbpedia_resource": "http://dbpedia.org/resource/December"}, {"text": "Bond", "relevance": 0.320126, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Contract", "relevance": 0.319817, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Short", "relevance": 0.30667, "dbpedia_resource": "http://dbpedia.org/resource/Short_(finance)"}], "categories": [{"score": 0.849946, "label": "/real estate/buying and selling homes"}, {"score": 0.800761, "label": "/finance/financial news"}, {"score": 0.789635, "label": "/finance/investing"}], "relations": [{"type": "populationOf", "sentence": "LONDON- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \"Code\") 1.", "score": 0.465196, "arguments": [{"text": "8.3", "location": [13, 16], "entities": [{"type": "Cardinal", "text": "8.3"}]}, {"text": "LONDON", "location": [0, 6], "entities": [{"type": "GeopoliticalEntity", "text": "LONDON"}]}]}, {"type": "diedOn", "sentence": "settled derivative transactions Class of Product Nature of dealing Number of Price per relevant description reference unit security securities Ordinary NPV SWAP Long 346 4,272.9893 JPY Ordinary NPV SWAP Long 460 4,272.9476 JPY Ordinary NPV SWAP Long 462 4,280.8218 JPY Ordinary NPV SWAP Long 1,682 4,272.1110 JPY Ordinary NPV SWAP Long 2,668 4,277.7399 JPY Ordinary NPV SWAP Long 6,282 4,276.4110 JPY Ordinary NPV SWAP Expires 20/02/2019 Long 199,900 4,304.0000 JPY Ordinary NPV SWAP Long 199,900 4,304.0000 JPY Ordinary NPV SWAP Short 94 4,271.4271 JPY Ordinary NPV SWAP Short 189 4,265.4265 JPY Ordinary NPV SWAP Short 472 4,282.6282 JPY Ordinary NPV SWAP Short 568 4,282.6070 JPY Ordinary NPV SWAP Short 600 4,290.1666 JPY Ordinary NPV SWAP Short 757 4,277.1776 JPY Ordinary NPV SWAP Short 897 4,272.6377 JPY Ordinary NPV SWAP Short 1,323 4,276.9422 JPY Ordinary NPV CFD Short 5,900 4,300.4300 JPY Ordinary NPV CFD Short 12,500 4,304.0000 JPY (c)", "score": 0.326664, "arguments": [{"text": "JPY Ordinary NPV SWAP Long", "location": [5373, 5399], "entities": [{"type": "Person", "text": "JPY Ordinary NPV SWAP Expires"}]}, {"text": "20/02/2019", "location": [5447, 5457], "entities": [{"type": "Date", "text": "20/02/2019"}]}]}, {"type": "agentOf", "sentence": "Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.796028, "arguments": [{"text": "i", "location": [6029, 6030], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Writing", "location": [6032, 6039], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [7003, 7009], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [7020, 7027], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "YES Date of disclosure: 23 Nov 2018 Contact name: Large Holdings Regulatory Operations Telephone number: 020 3134 7213 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.", "score": 0.817481, "arguments": [{"text": "Rule 8", "location": [7929, 7935], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [7943, 7947], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "employedBy", "sentence": "Note 5(i) on Rule 8 of the Takeover Code (the \"Code\") 1.", "score": 0.522588, "arguments": [{"text": "Rule 8", "location": [8375, 8381], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Takeover Code", "location": [8389, 8402], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [8010, 8034], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [8002, 8007], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [10521, 10545], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [10513, 10518], "entities": [{"type": "Organization", "text": "Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [8169, 8174], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [8188, 8215], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [10680, 10685], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [10699, 10726], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "managerOf", "sentence": "KEY INFORMATION Identity of the person whose positions/dealings Barclays PLC.", "score": 0.419441, "arguments": [{"text": "person", "location": [8451, 8457], "entities": [{"type": "Person", "text": "PERSON"}]}, {"text": "Barclays PLC", "location": [8483, 8495], "entities": [{"type": "Organization", "text": "BARCLAYS PLC Category Code", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Short Name: BARCLAYS PLC Category Code: RET Sequence Number: 659895 Time of Receipt (offset from UTC): 20181123T114352+0000 Contacts BARCLAYS PLC", "score": 0.488667, "arguments": [{"text": "UTC", "location": [10826, 10829], "entities": [{"type": "Organization", "text": "UTC"}]}, {"text": "Receipt", "location": [10805, 10812], "entities": [{"type": "GeopoliticalEntity", "text": "Receipt"}]}]}], "keywords": [{"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.73549, "count": 1}, {"text": "JPY Ordinary NPV Purchase", "sentiment": {"score": 0.828914, "label": "positive"}, "relevance": 0.706894, "count": 21}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.643956, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.624095, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.64284, "label": "positive"}, "relevance": 0.608965, "count": 4}, {"text": "short positions", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.599901, "count": 3}, {"text": "Purchases", "sentiment": {"score": 0.828914, "label": "positive"}, "relevance": 0.594875, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0.598359, "label": "positive"}, "relevance": 0.577888, "count": 2}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.577779, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.584183, "label": "positive"}, "relevance": 0.577345, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574636, "count": 1}, {"text": "options", "sentiment": {"score": 0.704899, "label": "positive"}, "relevance": 0.56774, "count": 4}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.566946, "count": 2}, {"text": "relevant Purchase", "sentiment": {"score": 0.828914, "label": "positive"}, "relevance": 0.562814, "count": 1}, {"text": "Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556727, "count": 1}, {"text": "Code", "sentiment": {"score": -0.29311, "mixed": "1", "label": "negative"}, "relevance": 0.554967, "count": 5}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.551872, "count": 1}, {"text": "Date position", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.543949, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541349, "count": 2}, {"text": "PERSON", "sentiment": {"score": 0.54238, "label": "positive"}, "relevance": 0.539667, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.539041, "count": 1}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.535994, "count": 2}, {"text": "Ordinary NPV Interests Short Positions Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535906, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.531708, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.531654, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.531654, "count": 1}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531404, "count": 2}, {"text": "disclosures", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.531325, "count": 1}, {"text": "positions", "sentiment": {"score": 0.806498, "label": "positive"}, "relevance": 0.529989, "count": 2}, {"text": "Class of relevant security", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.529837, "count": 2}, {"text": "relation", "sentiment": {"score": 0.664279, "label": "positive"}, "relevance": 0.52969, "count": 5}, {"text": "relevant securities of the offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527182, "count": 1}, {"text": "Sequence Number", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526919, "count": 1}, {"text": "Interests", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526057, "count": 1}, {"text": "Ordinary NPV Call Options", "sentiment": {"score": 0.839232, "label": "positive"}, "relevance": 0.525832, "count": 8}, {"text": "nature of the rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.52492, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52468, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.814317, "label": "positive"}, "relevance": 0.524019, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.523981, "count": 2}, {"text": "form", "sentiment": {"score": 0.479695, "label": "positive"}, "relevance": 0.523976, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.432114, "label": "positive"}, "relevance": 0.523976, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.523508, "count": 2}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522783, "count": 3}, {"text": "option", "sentiment": {"score": 0.736995, "label": "positive"}, "relevance": 0.522704, "count": 4}, {"text": "voting rights", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.522215, "count": 1}, {"text": "Class of Product Nature", "sentiment": {"score": 0.828914, "label": "positive"}, "relevance": 0.521023, "count": 1}, {"text": "details", "sentiment": {"score": 0.843569, "label": "positive"}, "relevance": 0.520811, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.520477, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.770001, "label": "positive"}, "relevance": 0.520456, "count": 3}, {"text": "Rule", "sentiment": {"score": -0.881961, "label": "negative"}, "relevance": 0.520342, "count": 2}]}, "extracted_metadata": {"sha1": "019f71f4b9a73c396a8a895fd6d3f4d4590190b6", "filename": "1542989711277.zip-824d34c3643eefa3e8ccb70331c63f11.xml", "file_type": "json"}, "title": "BARCLAYS PLC UK Regulatory Announcement: Form 8.3 - TAKEDA PHARMACEUTICAL CO LTD", "forum_title": "All News | Business Wire"}, {"id": "Rb8hEDt4zyHjZKucfrSWWAt0x6Ph3WN4IENNHnUizhqG9QADeofRpde_LUDG_2Bb", "result_metadata": {"score": 30.087414}, "author": "Hussain Shah", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Muscle", "relevance": 0.936186, "dbpedia_resource": "http://dbpedia.org/resource/Muscle"}, {"text": "Muscle atrophy", "relevance": 0.93288, "dbpedia_resource": "http://dbpedia.org/resource/Muscle_atrophy"}, {"text": "Atrophy", "relevance": 0.8879, "dbpedia_resource": "http://dbpedia.org/resource/Atrophy"}], "categories": [{"score": 0.765321, "label": "/health and fitness"}, {"score": 0.760781, "label": "/health and fitness/disorders"}, {"score": 0.75758, "label": "/health and fitness/disease"}], "relations": [], "keywords": [{"text": "Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.687236, "count": 1}, {"text": "Spinal Bulbar Muscular Atrophy Treatment Value Chain", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.607427, "count": 1}]}, "crawl_date": "2018-11-23T15:13:37Z", "url": "https://www.findmarketresearch.org/2018/11/spinal-bulbar-muscular-atrophy-treatment-market-value-chain-and-forecast-2018-2028/", "host": "findmarketresearch.org", "text": "., Takeda Pharmaceutical Company Limited, Century Pharmaceuticals Ltd, Johnson & Johnson, Astellas Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH, and Sanofi.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T08:35:00+05:00", "enriched_text": {"entities": [{"count": 7, "sentiment": {"score": -0.506277, "label": "negative"}, "text": "Kennedy disease", "relevance": 0.775571, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}, {"count": 4, "sentiment": {"score": 0.562848, "label": "positive"}, "text": "Western Europe", "relevance": 0.592145, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 2, "sentiment": {"score": 0.609427, "label": "positive"}, "text": "North America", "relevance": 0.394236, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.388207, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.847067, "label": "negative"}, "text": "muscle weakness", "relevance": 0.38276, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Muscle weakness", "dbpedia_resource": "http://dbpedia.org/resource/Muscle_weakness"}}, {"count": 2, "sentiment": {"score": -0.282642, "label": "negative"}, "text": "U.S.", "relevance": 0.381135, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Oxford University Press", "relevance": 0.336316, "type": "Organization", "disambiguation": {"subtype": ["Location", "Facility", "Company", "PeriodicalPublisher", "ProjectParticipant"], "name": "Oxford University Press", "dbpedia_resource": "http://dbpedia.org/resource/Oxford_University_Press"}}, {"count": 2, "sentiment": {"score": -0.824227, "label": "negative"}, "text": "pneumonia", "relevance": 0.31516, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Fasciculation", "relevance": 0.306767, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Finland", "relevance": 0.304358, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Profession", "Country"], "name": "Finland", "dbpedia_resource": "http://dbpedia.org/resource/Finland"}}, {"count": 2, "sentiment": {"score": -0.4103, "label": "negative"}, "text": "Dutasteride", "relevance": 0.304051, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Australia", "relevance": 0.302616, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Australia", "dbpedia_resource": "http://dbpedia.org/resource/Australia"}}, {"count": 1, "sentiment": {"score": 0.320999, "label": "positive"}, "text": "South America", "relevance": 0.302103, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.284321, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.277398, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eastern Europe", "relevance": 0.276029, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0.855365, "label": "positive"}, "text": "India", "relevance": 0.275757, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0.855365, "label": "positive"}, "text": "Asia Pacific", "relevance": 0.265269, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.261218, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi", "relevance": 0.259221, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.258532, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline plc.", "relevance": 0.256851, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.253497, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma", "relevance": 0.25169, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": 0.855365, "label": "positive"}, "text": "China", "relevance": 0.250866, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.250804, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.248264, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.242638, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim International GmbH", "relevance": 0.241851, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.4103, "label": "negative"}, "text": "leuprolide", "relevance": 0.240805, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.375305, "label": "negative"}, "text": "Century Pharmaceuticals Ltd", "relevance": 0.218803, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.213985, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "53.2 years", "relevance": 0.213985, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "65 years", "relevance": 0.213985, "type": "Quantity"}], "sentiment": {"document": {"score": 0.368258, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Spinal and bulbar muscular atrophy", "keywords": [{"text": "bulbar muscular atrophy"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "sentence": "Spinal and bulbar muscular atrophy is also called Kennedy disease.", "object": {"text": "called Kennedy disease", "keywords": [{"text": "Kennedy disease"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Spinal and bulbar muscular atrophy", "keywords": [{"text": "bulbar muscular atrophy"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "sentence": "Spinal and bulbar muscular atrophy is also called Kennedy disease.", "object": {"text": "Kennedy disease", "keywords": [{"text": "Kennedy disease"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "action": {"verb": {"text": "call", "tense": "past"}, "text": "is also called", "normalized": "be also call"}}, {"subject": {"text": "It"}, "sentence": " It is a disorder of the nerve cells that control muscle movement.", "object": {"text": "a disorder of the nerve cells that control muscle movement", "keywords": [{"text": "nerve cells"}, {"text": "muscle movement"}, {"text": "disorder"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the nerve cells", "keywords": [{"text": "nerve cells"}]}, "sentence": " It is a disorder of the nerve cells that control muscle movement.", "object": {"text": "muscle movement", "keywords": [{"text": "muscle movement"}]}, "action": {"verb": {"text": "control", "tense": "present"}, "text": "control", "normalized": "control"}}, {"subject": {"text": "These nerve cells", "keywords": [{"text": "nerve cells"}]}, "sentence": " These nerve cells are present in the brainstem.", "object": {"text": "present in the brainstem", "keywords": [{"text": "brainstem"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Spinal and bulbar muscular atrophy", "keywords": [{"text": "bulbar muscular atrophy"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "sentence": " Spinal and bulbar muscular atrophy mainly occurs in males, and is characterized by atrophy that usually arises in adulthood.", "object": {"text": "in males", "keywords": [{"text": "males"}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "atrophy", "keywords": [{"text": "atrophy"}]}, "sentence": " Spinal and bulbar muscular atrophy mainly occurs in males, and is characterized by atrophy that usually arises in adulthood.", "action": {"verb": {"text": "arise", "tense": "present"}, "text": "arises", "normalized": "arise"}}, {"subject": {"text": "Fasciculation\u2019s, unusual breast development, and infertility", "keywords": [{"text": "unusual breast development"}, {"text": "Fasciculation"}, {"text": "infertility"}], "entities": [{"type": "HealthCondition", "text": "Fasciculation"}]}, "sentence": " Fasciculation\u2019s, unusual breast development, and infertility are also observed in this disorder.", "action": {"verb": {"text": "observe", "tense": "past"}, "text": "are also observed", "normalized": "be also observe"}}, {"subject": {"text": "Spinal bulbar muscular atrophy", "keywords": [{"text": "bulbar muscular atrophy"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "sentence": " Spinal bulbar muscular atrophy has been diagnosed in the U.S., Europe, Asia, South America, and Australia.", "object": {"text": "diagnosed in the U.S., Europe, Asia, South America, and Australia", "keywords": [{"text": "South America"}, {"text": "U.S."}, {"text": "Europe"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"type": "Location", "text": "South America", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"type": "Location", "text": "Australia", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Australia", "dbpedia_resource": "http://dbpedia.org/resource/Australia"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Spinal bulbar muscular atrophy", "keywords": [{"text": "bulbar muscular atrophy"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "sentence": " Spinal bulbar muscular atrophy has been diagnosed in the U.S., Europe, Asia, South America, and Australia.", "action": {"verb": {"text": "diagnose", "tense": "past"}, "text": "has been diagnosed", "normalized": "have be diagnose"}}, {"subject": {"text": "The Japanese population", "keywords": [{"text": "Japanese population"}]}, "sentence": " The Japanese population is shown to have a very high occurrence.", "object": {"text": "shown to have a very high occurrence", "keywords": [{"text": "high occurrence"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Japanese population", "keywords": [{"text": "Japanese population"}]}, "sentence": " The Japanese population is shown to have a very high occurrence.", "object": {"text": "a very high occurrence", "keywords": [{"text": "high occurrence"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "is shown to have", "normalized": "be show to have"}}, {"subject": {"text": "Physical therapy, occupational therapy, and speech therapy", "keywords": [{"text": "occupational therapy"}, {"text": "Physical therapy"}, {"text": "speech"}], "entities": []}, "sentence": " Physical therapy, occupational therapy, and speech therapy are usually used to maintain individual skills.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Physical therapy, occupational therapy, and speech therapy", "keywords": [{"text": "occupational therapy"}, {"text": "Physical therapy"}, {"text": "speech"}], "entities": []}, "sentence": " Physical therapy, occupational therapy, and speech therapy are usually used to maintain individual skills.", "object": {"text": "to maintain individual skills", "keywords": [{"text": "individual skills"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "Physical therapy, occupational therapy, and speech therapy", "keywords": [{"text": "occupational therapy"}, {"text": "Physical therapy"}, {"text": "speech"}], "entities": []}, "sentence": " Physical therapy, occupational therapy, and speech therapy are usually used to maintain individual skills.", "object": {"text": "individual skills", "keywords": [{"text": "individual skills"}]}, "action": {"verb": {"text": "maintain", "tense": "future"}, "text": "to maintain", "normalized": "to maintain"}}, {"subject": {"text": "Braces and wheel chairs", "keywords": [{"text": "wheel chairs"}, {"text": "Braces"}]}, "sentence": " Braces and wheel chairs are used for ambulation.", "object": {"text": "for ambulation", "keywords": [{"text": "ambulation"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "are used", "normalized": "be use"}}, {"subject": {"text": "breast reduction physicians", "keywords": [{"text": "breast reduction physicians"}]}, "sentence": " For breast reduction physicians prefer surgery.", "object": {"text": "surgery", "keywords": [{"text": "surgery"}]}, "action": {"verb": {"text": "prefer", "tense": "present"}, "text": "prefer", "normalized": "prefer"}}, {"subject": {"text": "The growing number of incidences of spinal bulbar muscular atrophy", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "incidences"}, {"text": "number"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "sentence": " The growing number of incidences of spinal bulbar muscular atrophy is driving the growth of the market.", "object": {"text": "driving the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The growing number of incidences of spinal bulbar muscular atrophy", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "incidences"}, {"text": "number"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "sentence": " The growing number of incidences of spinal bulbar muscular atrophy is driving the growth of the market.", "object": {"text": "the growth of the market", "keywords": [{"text": "growth"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "is driving", "normalized": "be drive"}}, {"subject": {"text": "the growth of the spinal bulbar muscular atrophy treatment market", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "treatment market"}]}, "sentence": " Rapid turnaround time and lower cost of this procedure over conventional methods are also fueling the growth of the spinal bulbar muscular atrophy treatment market.", "object": {"text": "Rapid turnaround time and lower cost of this procedure over conventional methods", "keywords": [{"text": "Rapid turnaround time"}, {"text": "lower cost"}, {"text": "conventional methods"}, {"text": "procedure"}]}, "action": {"verb": {"text": "fuel", "tense": "present"}, "text": "fueling", "normalized": "fuel"}}, {"subject": {"text": "by the limited number of drugs available that inhibits in hormone level on the market", "keywords": [{"text": "hormone level"}, {"text": "inhibits"}, {"text": "drugs"}, {"text": "number"}], "entities": []}, "sentence": " However, the global market for spinal bulbar muscular atrophy treatment is expected to be deterred by the limited number of drugs available that inhibits in hormone level on the market.", "object": {"text": "the global market for spinal bulbar muscular atrophy treatment", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "global market"}, {"text": "treatment"}], "entities": []}, "action": {"verb": {"text": "deter", "tense": "past"}, "text": "is expected to be deterred", "normalized": "be expect to be deter"}}, {"subject": {"text": "Dutasteride and leuprolide", "keywords": [{"text": "Dutasteride"}, {"text": "leuprolide"}], "entities": [{"type": "Drug", "text": "Dutasteride"}, {"type": "Drug", "text": "leuprolide"}]}, "sentence": " Dutasteride and leuprolide are two drugs which are currently present around the world for spinal bulbar muscular atrophy treatment.", "object": {"text": "two drugs which are currently present around the world", "keywords": [{"text": "drugs"}, {"text": "world"}], "entities": [{"type": "Drug", "text": "Dutasteride"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "two drugs", "keywords": [{"text": "drugs"}], "entities": [{"type": "Drug", "text": "Dutasteride"}]}, "sentence": " Dutasteride and leuprolide are two drugs which are currently present around the world for spinal bulbar muscular atrophy treatment.", "object": {"text": "present around the world", "keywords": [{"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The occurrence rate of spinal bulbar muscular atrophy", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "occurrence rate"}], "entities": [{"type": "HealthCondition", "text": "Kennedy disease", "disambiguation": {"subtype": [], "name": "Spinal and bulbar muscular atrophy", "dbpedia_resource": "http://dbpedia.org/resource/Spinal_and_bulbar_muscular_atrophy"}}]}, "sentence": " The occurrence rate of spinal bulbar muscular atrophy is around 1 per 100,000 individuals, and high incidences are observed in Finland.", "object": {"text": "around 1 per 100,000 individuals", "keywords": [{"text": "100,000"}, {"text": "individuals"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "From the 2005\u20132006 National Health and Nutrition Examination Survey", "keywords": [{"text": "Nutrition Examination Survey"}, {"text": "National Health"}]}, "sentence": " From the 2005\u20132006 National Health and Nutrition Examination Survey using a sample of 1480 men with a mean age of 53.2 years (range 37\u201379) with spinal bulbar muscular atrophy disorder were obtained for the hormonal profile, healthy control mean values and standard errors and according to the Oxford University Press, in 2006 a study followed 223 Japanese spinal bulbar muscular atrophy patients for a number of years, and among them, 15 died, with a median age of 65 years.", "object": {"text": "a sample of 1480 men", "keywords": [{"text": "sample"}, {"text": "men"}]}, "action": {"verb": {"text": "use", "tense": "present"}, "text": "using", "normalized": "use"}}, {"subject": {"text": "spinal bulbar muscular atrophy disorder", "keywords": [{"text": "bulbar muscular atrophy"}]}, "sentence": " From the 2005\u20132006 National Health and Nutrition Examination Survey using a sample of 1480 men with a mean age of 53.2 years (range 37\u201379) with spinal bulbar muscular atrophy disorder were obtained for the hormonal profile, healthy control mean values and standard errors and according to the Oxford University Press, in 2006 a study followed 223 Japanese spinal bulbar muscular atrophy patients for a number of years, and among them, 15 died, with a median age of 65 years.", "object": {"text": "obtained for the hormonal profile", "keywords": [{"text": "hormonal profile"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "From the 2005\u20132006 National Health and Nutrition Examination Survey using a sample of 1480 men with a mean age of 53.2 years (range 37\u201379)", "keywords": [{"text": "Nutrition Examination Survey"}, {"text": "mean age"}, {"text": "National Health"}, {"text": "sample"}], "entities": [{"type": "Quantity", "text": "53.2 years"}]}, "sentence": " From the 2005\u20132006 National Health and Nutrition Examination Survey using a sample of 1480 men with a mean age of 53.2 years (range 37\u201379) with spinal bulbar muscular atrophy disorder were obtained for the hormonal profile, healthy control mean values and standard errors and according to the Oxford University Press, in 2006 a study followed 223 Japanese spinal bulbar muscular atrophy patients for a number of years, and among them, 15 died, with a median age of 65 years.", "object": {"text": "to the Oxford University Press, in 2006 a study followed 223 Japanese spinal bulbar muscular atrophy patients for a number of years, and among them, 15 died, with a median age of 65 years", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "Oxford University Press"}, {"text": "median age"}], "entities": [{"type": "Organization", "text": "Oxford University Press", "disambiguation": {"subtype": ["Location", "Facility", "Company", "PeriodicalPublisher", "ProjectParticipant"], "name": "Oxford University Press", "dbpedia_resource": "http://dbpedia.org/resource/Oxford_University_Press"}}, {"type": "Quantity", "text": "65 years"}]}, "action": {"verb": {"text": "accord", "tense": "present"}, "text": "according", "normalized": "accord"}}, {"subject": {"text": "A common cause of death for spinal bulbar muscular atrophy patients", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "common cause"}], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}, "sentence": " A common cause of death for spinal bulbar muscular atrophy patients was pneumonia and respiratory failure.", "object": {"text": "pneumonia and respiratory failure", "keywords": [{"text": "respiratory failure"}, {"text": "pneumonia"}], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " A geographic condition regarding spinal bulbar muscular atrophy treatment market, it has been segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and Asia-Pacific excluding Japan, Japan, and the Middle East & Africa.", "object": {"text": "been segmented into seven key regions", "keywords": [{"text": "key regions"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "it"}, "sentence": " A geographic condition regarding spinal bulbar muscular atrophy treatment market, it has been segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and Asia-Pacific excluding Japan, Japan, and the Middle East & Africa.", "object": {"text": "into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and Asia-Pacific excluding Japan, Japan, and the Middle East & Africa", "keywords": [{"text": "key regions"}, {"text": "Middle East"}, {"text": "North America"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Eastern Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"type": "Location", "text": "Africa", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is expected to represent huge contribution under spinal bulbar muscular atrophy treatment by revenue generation.", "object": {"text": "huge contribution", "keywords": [{"text": "huge contribution"}]}, "action": {"verb": {"text": "represent", "tense": "future"}, "text": "is expected to represent", "normalized": "be expect to represent"}}, {"subject": {"text": "high spending on innovative work in Europe", "keywords": [{"text": "high spending"}, {"text": "innovative work"}, {"text": "Europe"}], "entities": [{"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Quickened development on the improvement of new items and high spending on innovative work in Europe demonstrates the elevation of the spinal bulbar muscular atrophy treatment market.", "object": {"text": "the elevation of the spinal bulbar muscular atrophy treatment market", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "elevation"}, {"text": "treatment market"}]}, "action": {"verb": {"text": "demonstrate", "tense": "present"}, "text": "demonstrates", "normalized": "demonstrate"}}, {"subject": {"text": "China", "keywords": [{"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " With ascending in standards of health care services and increase in mindfulness towards the medications in India and China is relied upon to support the market for spinal bulbar muscular atrophy treatment in general Asia Pacific area.", "object": {"text": "to support the market for spinal bulbar muscular atrophy treatment in general Asia Pacific area", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "general Asia Pacific"}, {"text": "market"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "Asia Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "action": {"verb": {"text": "rely", "tense": "past"}, "text": "is relied", "normalized": "be rely"}}, {"subject": {"text": "health care services and increase in mindfulness towards the medications in India and China", "keywords": [{"text": "health care services"}, {"text": "mindfulness"}, {"text": "medications"}, {"text": "India"}], "entities": [{"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " With ascending in standards of health care services and increase in mindfulness towards the medications in India and China is relied upon to support the market for spinal bulbar muscular atrophy treatment in general Asia Pacific area.", "object": {"text": "the market for spinal bulbar muscular atrophy treatment in general Asia Pacific area", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "general Asia Pacific"}, {"text": "market"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "Asia Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "action": {"verb": {"text": "support", "tense": "future"}, "text": "to support", "normalized": "to support"}}, {"subject": {"text": "Some of the players", "keywords": [{"text": "players"}]}, "sentence": " Some of the players identified in the spinal bulbar muscular atrophy treatment market include GlaxoSmithKline plc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Century Pharmaceuticals Ltd, Johnson & Johnson, Astellas Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH, and Sanofi.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "GlaxoSmithKline plc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Century Pharmaceuticals Ltd, Johnson & Johnson, Astellas Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "Ingelheim International GmbH"}, {"text": "GlaxoSmithKline plc."}, {"text": "Century Pharmaceuticals"}], "entities": [{"type": "Company", "text": "GlaxoSmithKline plc."}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Century Pharmaceuticals Ltd"}, {"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "Astellas Pharma", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Boehringer Ingelheim International GmbH"}]}, "sentence": " Some of the players identified in the spinal bulbar muscular atrophy treatment market include GlaxoSmithKline plc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Century Pharmaceuticals Ltd, Johnson & Johnson, Astellas Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH, and Sanofi.", "object": {"text": "Some of the players identified in the spinal bulbar muscular atrophy treatment market", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "treatment market"}, {"text": "players"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "The spinal bulbar muscular atrophy treatment market report", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "treatment market report"}]}, "sentence": " The spinal bulbar muscular atrophy treatment market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, and inputs from industry experts and industry participants across the value chain.", "object": {"text": "a compilation of first-hand information, qualitative and quantitative assessment by industry analysts", "keywords": [{"text": "first-hand information"}, {"text": "industry analysts"}, {"text": "quantitative assessment"}, {"text": "compilation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment.", "object": {"text": "an in-depth analysis of parent market trends, macro-economic indicators, and governing factors, along with market attractiveness as per segment", "keywords": [{"text": "parent market trends"}, {"text": "macro-economic indicators"}, {"text": "market attractiveness"}, {"text": "in-depth analysis"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "The spinal bulbar muscular atrophy treatment market report", "keywords": [{"text": "bulbar muscular atrophy"}, {"text": "treatment market report"}]}, "sentence": " The spinal bulbar muscular atrophy treatment market report also maps the qualitative impact of various market factors on market segments and geographies.", "object": {"text": "the qualitative impact of various market factors on market segments and geographies", "keywords": [{"text": "various market factors"}, {"text": "qualitative impact"}, {"text": "market segments"}, {"text": "geographies"}]}, "action": {"verb": {"text": "map", "tense": "present"}, "text": "maps", "normalized": "map"}}], "concepts": [{"text": "Muscle", "relevance": 0.989167, "dbpedia_resource": "http://dbpedia.org/resource/Muscle"}, {"text": "Nerve", "relevance": 0.692932, "dbpedia_resource": "http://dbpedia.org/resource/Nerve"}, {"text": "North America", "relevance": 0.67976, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Qualitative research", "relevance": 0.668214, "dbpedia_resource": "http://dbpedia.org/resource/Qualitative_research"}, {"text": "Muscle atrophy", "relevance": 0.652449, "dbpedia_resource": "http://dbpedia.org/resource/Muscle_atrophy"}, {"text": "Europe", "relevance": 0.648613, "dbpedia_resource": "http://dbpedia.org/resource/Europe"}, {"text": "Atrophy", "relevance": 0.61455, "dbpedia_resource": "http://dbpedia.org/resource/Atrophy"}, {"text": "United States", "relevance": 0.568671, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.55954, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Muscle contraction", "relevance": 0.549347, "dbpedia_resource": "http://dbpedia.org/resource/Muscle_contraction"}, {"text": "Muscular system", "relevance": 0.542052, "dbpedia_resource": "http://dbpedia.org/resource/Muscular_system"}, {"text": "Muscle weakness", "relevance": 0.526319, "dbpedia_resource": "http://dbpedia.org/resource/Muscle_weakness"}, {"text": "Eastern Europe", "relevance": 0.501264, "dbpedia_resource": "http://dbpedia.org/resource/Eastern_Europe"}, {"text": "Japan", "relevance": 0.459613, "dbpedia_resource": "http://dbpedia.org/resource/Japan"}, {"text": "Mean", "relevance": 0.455747, "dbpedia_resource": "http://dbpedia.org/resource/Mean"}, {"text": "South America", "relevance": 0.454663, "dbpedia_resource": "http://dbpedia.org/resource/South_America"}, {"text": "Central Europe", "relevance": 0.451407, "dbpedia_resource": "http://dbpedia.org/resource/Central_Europe"}, {"text": "Boehringer Ingelheim", "relevance": 0.441105, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Western Europe", "relevance": 0.426364, "dbpedia_resource": "http://dbpedia.org/resource/Western_Europe"}, {"text": "Progressive bulbar palsy", "relevance": 0.426052, "dbpedia_resource": "http://dbpedia.org/resource/Progressive_bulbar_palsy"}, {"text": "Asia-Pacific", "relevance": 0.425944, "dbpedia_resource": "http://dbpedia.org/resource/Asia-Pacific"}, {"text": "GlaxoSmithKline", "relevance": 0.416844, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Latin America", "relevance": 0.41553, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Spain", "relevance": 0.407248, "dbpedia_resource": "http://dbpedia.org/resource/Spain"}], "categories": [{"score": 0.987504, "label": "/health and fitness"}, {"score": 0.954812, "label": "/health and fitness/disorders"}, {"score": 0.929843, "label": "/health and fitness/disease"}], "relations": [{"type": "agentOf", "sentence": "Spinal and bulbar muscular atrophy is also called Kennedy disease.", "score": 0.822033, "arguments": [{"text": "Kennedy", "location": [50, 57], "entities": [{"type": "Person", "text": "Kennedy"}]}, {"text": "called", "location": [43, 49], "entities": [{"type": "EventCommunication", "text": "called"}]}]}, {"type": "locatedAt", "sentence": "A geographic condition regarding spinal bulbar muscular atrophy treatment market, it has been segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and Asia-Pacific excluding Japan, Japan, and the Middle East & Africa.", "score": 0.453991, "arguments": [{"text": "regions", "location": [2849, 2856], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [2873, 2886], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "A geographic condition regarding spinal bulbar muscular atrophy treatment market, it has been segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and Asia-Pacific excluding Japan, Japan, and the Middle East & Africa.", "score": 0.52377, "arguments": [{"text": "regions", "location": [2849, 2856], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Eastern Europe", "location": [2888, 2902], "entities": [{"type": "GeopoliticalEntity", "text": "Eastern Europe"}]}]}, {"type": "locatedAt", "sentence": "A geographic condition regarding spinal bulbar muscular atrophy treatment market, it has been segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and Asia-Pacific excluding Japan, Japan, and the Middle East & Africa.", "score": 0.471696, "arguments": [{"text": "regions", "location": [2849, 2856], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Western Europe", "location": [2904, 2918], "entities": [{"type": "GeopoliticalEntity", "text": "Western Europe"}]}]}, {"type": "locatedAt", "sentence": "A geographic condition regarding spinal bulbar muscular atrophy treatment market, it has been segmented into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and Asia-Pacific excluding Japan, Japan, and the Middle East & Africa.", "score": 0.664343, "arguments": [{"text": "Eastern Europe", "location": [2888, 2902], "entities": [{"type": "GeopoliticalEntity", "text": "Eastern Europe"}]}, {"text": "Western Europe", "location": [2904, 2918], "entities": [{"type": "GeopoliticalEntity", "text": "Western Europe"}]}]}, {"type": "locatedAt", "sentence": "With ascending in standards of health care services and increase in mindfulness towards the medications in India and China is relied upon to support the market for spinal bulbar muscular atrophy treatment in general Asia Pacific area.", "score": 0.600038, "arguments": [{"text": "medications", "location": [3394, 3405], "entities": [{"type": "Substance", "text": "medications"}]}, {"text": "India", "location": [3409, 3414], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "With ascending in standards of health care services and increase in mindfulness towards the medications in India and China is relied upon to support the market for spinal bulbar muscular atrophy treatment in general Asia Pacific area.", "score": 0.504247, "arguments": [{"text": "Asia", "location": [3518, 3522], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [3523, 3530], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "With ascending in standards of health care services and increase in mindfulness towards the medications in India and China is relied upon to support the market for spinal bulbar muscular atrophy treatment in general Asia Pacific area.", "score": 0.634882, "arguments": [{"text": "area", "location": [3531, 3535], "entities": [{"type": "GeopoliticalEntity", "text": "area"}]}, {"text": "Pacific", "location": [3523, 3530], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "partOfMany", "sentence": "Some of the players identified in the spinal bulbar muscular atrophy treatment market include GlaxoSmithKline plc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Century Pharmaceuticals Ltd, Johnson & Johnson, Astellas Pharma, Pfizer Inc., Boehringer Ingelheim International GmbH, and Sanofi.", "score": 0.923933, "arguments": [{"text": "Some", "location": [3537, 3541], "entities": [{"type": "Cardinal", "text": "Some"}]}, {"text": "players", "location": [3549, 3556], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "partOfMany", "sentence": "The Japanese population is shown to have a very high occurrence.", "score": 0.943357, "arguments": [{"text": "population", "location": [707, 717], "entities": [{"type": "Person", "text": "population"}]}, {"text": "Japanese", "location": [698, 706], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "affectedBy", "sentence": "For breast reduction physicians prefer surgery.", "score": 0.844036, "arguments": [{"text": "physicians", "location": [995, 1005], "entities": [{"type": "Person", "text": "physicians"}]}, {"text": "reduction", "location": [985, 994], "entities": [{"type": "EventPersonnel", "text": "reduction"}]}]}, {"type": "locatedAt", "sentence": "A reimbursement process is also available in many regions like the U.S., Europe, and Japan.", "score": 0.879159, "arguments": [{"text": "regions", "location": [1414, 1421], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "U.S.", "location": [1431, 1435], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "A reimbursement process is also available in many regions like the U.S., Europe, and Japan.", "score": 0.933125, "arguments": [{"text": "regions", "location": [1414, 1421], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [1437, 1443], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "A reimbursement process is also available in many regions like the U.S., Europe, and Japan.", "score": 0.658052, "arguments": [{"text": "regions", "location": [1414, 1421], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Japan", "location": [1449, 1454], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "From the 2005-2006 National Health and Nutrition Examination Survey using a sample of 1480 men with a mean age of 53.2 years (range 37-79) with spinal bulbar muscular atrophy disorder were obtained for the hormonal profile, healthy control mean values and standard errors and according to the Oxford University Press, in 2006 a study followed 223 Japanese spinal bulbar muscular atrophy patients for a number of years, and among them, 15 died, with a median age of 65 years.", "score": 0.634908, "arguments": [{"text": "patients", "location": [2297, 2305], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "Japanese", "location": [2257, 2265], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "A common cause of death for spinal bulbar muscular atrophy patients was pneumonia and respiratory failure.", "score": 0.943767, "arguments": [{"text": "patients", "location": [2444, 2452], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "pneumonia", "location": [2457, 2466], "entities": [{"type": "HealthCondition", "text": "pneumonia"}]}]}, {"type": "hasAttribute", "sentence": "A common cause of death for spinal bulbar muscular atrophy patients was pneumonia and respiratory failure.", "score": 0.782655, "arguments": [{"text": "patients", "location": [2444, 2452], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "respiratory failure", "location": [2471, 2490], "entities": [{"type": "HealthCondition", "text": "respiratory failure"}]}]}], "keywords": [{"text": "bulbar muscular atrophy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.848022, "count": 2}, {"text": "Spinal bulbar muscular atrophy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.737039, "count": 1}, {"text": "spinal bulbar muscular atrophy", "sentiment": {"score": 0.550365, "label": "positive"}, "relevance": 0.62192, "count": 1}, {"text": "bulbar muscular atrophy results", "sentiment": {"score": -0.500396, "label": "negative"}, "relevance": 0.606971, "count": 1}, {"text": "Japanese population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570438, "count": 1}, {"text": "National Health", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569459, "count": 1}, {"text": "Oxford University Press", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569106, "count": 1}, {"text": "Physical therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.558742, "count": 1}, {"text": "disorder of the nerve cells", "sentiment": {"score": -0.785546, "label": "negative"}, "relevance": 0.55778, "count": 1}, {"text": "South America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556813, "count": 1}, {"text": "North America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551804, "count": 2}, {"text": "atrophy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.550436, "count": 1}, {"text": "mean age", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.549868, "count": 1}, {"text": "growth of the market", "sentiment": {"score": -0.47052, "mixed": "1", "label": "negative"}, "relevance": 0.549175, "count": 1}, {"text": "unusual breast development", "sentiment": {"score": -0.594055, "label": "negative"}, "relevance": 0.547895, "count": 1}, {"text": "standard errors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547705, "count": 1}, {"text": "spinal bulbar muscular atrophy treatment", "sentiment": {"score": 0.705575, "mixed": "1", "label": "positive"}, "relevance": 0.545402, "count": 5}, {"text": "Rapid turnaround time", "sentiment": {"score": 0.601292, "label": "positive"}, "relevance": 0.544832, "count": 1}, {"text": "report", "sentiment": {"score": 0.613061, "label": "positive"}, "relevance": 0.543729, "count": 1}, {"text": "global market", "sentiment": {"score": -0.660226, "label": "negative"}, "relevance": 0.542749, "count": 1}, {"text": "disorder", "sentiment": {"score": -0.594055, "label": "negative"}, "relevance": 0.54199, "count": 1}, {"text": "growing demand", "sentiment": {"score": 0.969243, "label": "positive"}, "relevance": 0.537725, "count": 1}, {"text": "bulbar muscles", "sentiment": {"score": -0.697347, "label": "negative"}, "relevance": 0.535616, "count": 1}, {"text": "occupational therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534265, "count": 1}, {"text": "conventional methods", "sentiment": {"score": 0.601292, "label": "positive"}, "relevance": 0.532103, "count": 1}, {"text": "innovative work", "sentiment": {"score": 0.929177, "label": "positive"}, "relevance": 0.532086, "count": 1}, {"text": "industry experts", "sentiment": {"score": 0.876214, "label": "positive"}, "relevance": 0.531172, "count": 1}, {"text": "market", "sentiment": {"score": 0.991355, "label": "positive"}, "relevance": 0.530347, "count": 2}, {"text": "huge contribution", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529877, "count": 1}, {"text": "limited number of drugs", "sentiment": {"score": -0.660226, "label": "negative"}, "relevance": 0.529594, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527006, "count": 1}, {"text": "spinal bulbar muscular atrophy patients", "sentiment": {"score": -0.66099, "label": "negative"}, "relevance": 0.52681, "count": 2}, {"text": "Europe", "sentiment": {"score": 0.52812, "mixed": "1", "label": "positive"}, "relevance": 0.525756, "count": 3}, {"text": "standards of health care services", "sentiment": {"score": 0.991355, "label": "positive"}, "relevance": 0.525586, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": -0.392869, "label": "negative"}, "relevance": 0.524433, "count": 1}, {"text": "value chain", "sentiment": {"score": 0.613061, "label": "positive"}, "relevance": 0.524231, "count": 1}, {"text": "development", "sentiment": {"score": 0.929177, "label": "positive"}, "relevance": 0.523884, "count": 1}, {"text": "Eastern Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523782, "count": 1}, {"text": "mean values", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522884, "count": 1}, {"text": "Reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521907, "count": 1}, {"text": "control muscle movement", "sentiment": {"score": -0.785546, "label": "negative"}, "relevance": 0.521857, "count": 1}, {"text": "nerve cells", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521805, "count": 1}, {"text": "companies", "sentiment": {"score": 0.969243, "label": "positive"}, "relevance": 0.521242, "count": 1}, {"text": "Johnson", "sentiment": {"score": -0.392869, "label": "negative"}, "relevance": 0.520844, "count": 2}, {"text": "Western Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520222, "count": 1}, {"text": "speech therapy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519608, "count": 1}, {"text": "spinal bulbar muscular atrophy disorder", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518789, "count": 1}, {"text": "market segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518267, "count": 1}, {"text": "regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51811, "count": 1}, {"text": "study", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517532, "count": 1}]}, "extracted_metadata": {"sha1": "1d71538ce71aba0122d99d165afdd7ff547099e3", "filename": "1542986017252.zip-8a43afa10dba23223eb03a019112e20e.xml", "file_type": "json"}, "external_links": ["https://www.factmr.com/connectus/sample?flag=RC&rep_id=1221", "https://www.factmr.com/report/1221/spinal-bulbar-muscular-atrophy-treatment-market"], "title": "Spinal Bulbar Muscular Atrophy Treatment Value Chain and Forecast 2018-2028", "forum_title": "Research Insights | Find Market Research - Part 34"}, {"id": "FGaI8lBhdMPGPj8Na5piJh_Hm37X1CWA3rJfsgHUhXQg8jzijqsCkvfPD8TiR_pm", "result_metadata": {"score": 26.164356}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.999993, "label": "/news/national news"}, {"score": 0.999987, "label": "/business and industrial/business news"}, {"score": 0.952853, "label": "/news/international news"}], "relations": [], "keywords": [{"text": "Wire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999596, "count": 1}, {"text": "News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.950907, "count": 1}, {"text": "myScience", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315024, "count": 1}]}, "crawl_date": "2018-11-23T17:26:10Z", "url": "https://www.myscience.org.uk/news/wire/mhh_freunde_foerdern_forscher-2018-MHH", "host": "myscience.org.uk", "text": "Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Life Sciences", "relevance": 0.836245, "type": "Organization", "disambiguation": {"subtype": [], "name": "Life sciences", "dbpedia_resource": "http://dbpedia.org/resource/Life_sciences"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Earth Sciences - Life Sciences", "relevance": 0.675389, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.615765, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.494541, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cardiff University", "relevance": 0.479784, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Nottingham", "relevance": 0.360988, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Nottingham", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Nottingham"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Universities of Bristol", "relevance": 0.339358, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Research Council", "relevance": 0.32913, "type": "Organization", "disambiguation": {"subtype": [], "name": "Medical Research Council (United Kingdom)", "dbpedia_resource": "http://dbpedia.org/resource/Medical_Research_Council_(United_Kingdom)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "James River", "relevance": 0.313604, "type": "GeographicFeature"}, {"count": 1, "sentiment": {"score": 0.665961, "label": "positive"}, "text": "Scottish government", "relevance": 0.304567, "type": "Organization", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Virginia", "relevance": 0.298225, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Virginia", "dbpedia_resource": "http://dbpedia.org/resource/Virginia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRC", "relevance": 0.294256, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.288952, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tennessee", "relevance": 0.286911, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}], "sentiment": {"document": {"score": 0.284597, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Archaeologists from the Universities of Bristol and Tennessee", "keywords": [{"text": "Archaeologists"}, {"text": "Universities"}, {"text": "Bristol"}, {"text": "Tennessee"}], "entities": [{"type": "Organization", "text": "Universities of Bristol"}, {"type": "Location", "text": "Tennessee", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "object": {"text": "located evidence for the site of America's first English Thanksgiving on the James River in Virginia", "keywords": [{"text": "James River"}, {"text": "Thanksgiving"}, {"text": "evidence"}, {"text": "site"}], "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "GeographicFeature", "text": "James River"}, {"type": "Location", "text": "Virginia", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Virginia", "dbpedia_resource": "http://dbpedia.org/resource/Virginia"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Archaeologists from the Universities of Bristol and Tennessee", "keywords": [{"text": "Archaeologists"}, {"text": "Universities"}, {"text": "Bristol"}, {"text": "Tennessee"}], "entities": [{"type": "Organization", "text": "Universities of Bristol"}, {"type": "Location", "text": "Tennessee", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "object": {"text": "evidence", "keywords": [{"text": "evidence"}]}, "action": {"verb": {"text": "locate", "tense": "past"}, "text": "have located", "normalized": "have locate"}}, {"subject": {"text": "by the University of Nottingham", "keywords": [{"text": "Nottingham"}, {"text": "University"}], "entities": [{"type": "Organization", "text": "University of Nottingham", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Nottingham", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Nottingham"}}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "19.11.2018 A research team", "keywords": [{"text": "research team"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "by the the Medical Research Council (MRC)", "keywords": [{"text": "MRC"}, {"text": "Medical Research Council"}], "entities": [{"type": "Organization", "text": "Medical Research Council", "disambiguation": {"subtype": [], "name": "Medical Research Council (United Kingdom)", "dbpedia_resource": "http://dbpedia.org/resource/Medical_Research_Council_(United_Kingdom)"}}, {"type": "Organization", "text": "MRC"}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "a grant", "keywords": [{"text": "grant"}]}, "action": {"verb": {"text": "award", "tense": "past"}, "text": "has been awarded", "normalized": "have be award"}}, {"subject": {"text": "the clinical translation of renal imaging and transform the way kidney disease", "keywords": [{"text": "way kidney disease"}, {"text": "renal imaging"}, {"text": "clinical translation"}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "diagnosed"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "treating psychiatric disorders Cardiff University", "keywords": [{"text": "psychiatric disorders Cardiff"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "sentence": " Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "object": {"text": "a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "drug discovery collaboration"}, {"text": "psychiatric disorders"}, {"text": "new approaches"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has formed", "normalized": "have form"}}, {"subject": {"text": "Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University", "keywords": [{"text": "psychiatric disorders Cardiff"}, {"text": "New approaches"}, {"text": "Earth Sciences"}, {"text": "Life Sciences"}], "entities": [{"type": "Organization", "text": "Earth Sciences - Life Sciences"}, {"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "sentence": " Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "object": {"text": "a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "drug discovery collaboration"}, {"text": "psychiatric disorders"}, {"text": "new approaches"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "form", "tense": "past"}, "text": "has formed", "normalized": "have form"}}, {"subject": {"text": "19.11.2018 With lowest cost green energy", "keywords": [{"text": "lowest cost green"}, {"text": "energy"}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "the future", "keywords": [{"text": "future"}]}, "action": {"verb": {"text": "consider", "tense": "past"}, "text": "considered", "normalized": "consider"}}, {"subject": {"text": "Computer Science / Telecom", "keywords": [{"text": "Telecom"}, {"text": "Science"}], "entities": []}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future", "keywords": [{"text": "onshore wind farms"}, {"text": "affordable wind power"}, {"text": "industry desire"}, {"text": "Scottish government"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understanding", "normalized": "understand"}}, {"subject": {"text": "understanding how to \u2018repower' existing onshore wind farms", "keywords": [{"text": "onshore wind farms"}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "the Scottish government", "keywords": [{"text": "Scottish government"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "supports", "normalized": "support"}}, {"subject": {"text": "the Scottish government and industry", "keywords": [{"text": "Scottish government"}, {"text": "industry"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "affordable wind power", "keywords": [{"text": "affordable wind"}, {"text": "power"}], "entities": []}, "action": {"verb": {"text": "generate", "tense": "future"}, "text": "to generate", "normalized": "to generate"}}], "concepts": [{"text": "Genetics", "relevance": 0.96581, "dbpedia_resource": "http://dbpedia.org/resource/Genetics"}, {"text": "Pharmacology", "relevance": 0.956142, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Nutrition", "relevance": 0.878096, "dbpedia_resource": "http://dbpedia.org/resource/Nutrition"}, {"text": "Psychiatry", "relevance": 0.822709, "dbpedia_resource": "http://dbpedia.org/resource/Psychiatry"}, {"text": "Medicine", "relevance": 0.809112, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical industry", "relevance": 0.792414, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Wind farm", "relevance": 0.772576, "dbpedia_resource": "http://dbpedia.org/resource/Wind_farm"}, {"text": "Mental disorder", "relevance": 0.75695, "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.745731, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Clinical trial", "relevance": 0.714706, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Wind power", "relevance": 0.709195, "dbpedia_resource": "http://dbpedia.org/resource/Wind_power"}, {"text": "Science", "relevance": 0.681694, "dbpedia_resource": "http://dbpedia.org/resource/Science"}, {"text": "Drug development", "relevance": 0.654584, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Drug discovery", "relevance": 0.651247, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Gene", "relevance": 0.644384, "dbpedia_resource": "http://dbpedia.org/resource/Gene"}, {"text": "Wind", "relevance": 0.641573, "dbpedia_resource": "http://dbpedia.org/resource/Wind"}], "categories": [{"score": 0.912367, "label": "/science/medicine/medical research"}, {"score": 0.886062, "label": "/business and industrial/energy/renewable energy/wind energy"}, {"score": 0.847148, "label": "/health and fitness/disorders"}], "relations": [{"type": "locatedAt", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.865818, "arguments": [{"text": "site", "location": [92, 96], "entities": [{"type": "Location", "text": "site"}]}, {"text": "America", "location": [100, 107], "entities": [{"type": "GeopoliticalEntity", "text": "America", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.736589, "arguments": [{"text": "site", "location": [92, 96], "entities": [{"type": "Location", "text": "site"}]}, {"text": "English", "location": [116, 123], "entities": [{"type": "GeopoliticalEntity", "text": "English"}]}]}, {"type": "partOfMany", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.820195, "arguments": [{"text": "Thanksgiving", "location": [124, 136], "entities": [{"type": "Person", "text": "Thanksgiving"}]}, {"text": "English", "location": [116, 123], "entities": [{"type": "GeopoliticalEntity", "text": "English"}]}]}, {"type": "residesIn", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.732729, "arguments": [{"text": "James River", "location": [144, 155], "entities": [{"type": "Person", "text": "James River"}]}, {"text": "Virginia", "location": [159, 167], "entities": [{"type": "GeopoliticalEntity", "text": "Virginia"}]}]}, {"type": "agentOf", "sentence": "Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "score": 0.614282, "arguments": [{"text": "Medical Research Council", "location": [293, 317], "entities": [{"type": "Organization", "text": "Medical Research Council"}]}, {"text": "awarded", "location": [266, 273], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "agentOf", "sentence": "Life Sciences - Agronomy / Food Science - 19.11.2018 There is an urgent need for new dietary approaches and treatments to tackle the global health crisis of obesity in children and adults say experts.", "score": 0.69565, "arguments": [{"text": "adults", "location": [1144, 1150], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "say", "location": [1151, 1154], "entities": [{"type": "EventCommunication", "text": "say"}]}]}], "keywords": [{"text": "Life Sciences", "sentiment": {"score": -0.656557, "label": "negative"}, "relevance": 0.949396, "count": 4}, {"text": "Earth Sciences", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.840453, "count": 1}, {"text": "Universities of Bristol", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672122, "count": 1}, {"text": "Food Science", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.648895, "count": 1}, {"text": "research team", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.64359, "count": 1}, {"text": "drug discovery collaboration", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.634426, "count": 1}, {"text": "Medical Research Council", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.601073, "count": 1}, {"text": "psychiatric disorders Cardiff University", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.596053, "count": 1}, {"text": "collaboration", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.590331, "count": 1}, {"text": "lowest cost", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.585581, "count": 1}, {"text": "green energy", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.581693, "count": 1}, {"text": "psychiatric disorders", "sentiment": {"score": -0.37013, "mixed": "1", "label": "negative"}, "relevance": 0.576386, "count": 1}, {"text": "New approaches", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.5751, "count": 1}, {"text": "urgent need", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.574867, "count": 1}, {"text": "Scottish government", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.570715, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.564555, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.562587, "count": 1}, {"text": "Computer Science", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.559528, "count": 1}, {"text": "University of Nottingham", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.555807, "count": 1}, {"text": "Agronomy", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.553495, "count": 1}, {"text": "Archaeologists", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542134, "count": 1}, {"text": "Music", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.541937, "count": 1}, {"text": "Telecom", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.534746, "count": 1}, {"text": "grant", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.532393, "count": 1}, {"text": "genomics", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.528277, "count": 1}, {"text": "neuroscience", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.52763, "count": 1}, {"text": "James River", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527316, "count": 1}, {"text": "MRC", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.525936, "count": 1}, {"text": "Tennessee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525603, "count": 1}, {"text": "treatments", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.524143, "count": 1}, {"text": "evidence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522629, "count": 1}, {"text": "University's large scale", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.521522, "count": 1}, {"text": "schizophrenia", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.51951, "count": 1}, {"text": "children", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.512786, "count": 1}, {"text": "onshore wind farms", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.510958, "count": 1}, {"text": "adults", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.510546, "count": 1}, {"text": "world-class expertise", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.50856, "count": 1}, {"text": "Virginia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507174, "count": 1}, {"text": "experts", "sentiment": {"score": 0.537436, "mixed": "1", "label": "positive"}, "relevance": 0.507174, "count": 1}, {"text": "clinical translation of renal imaging", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.504165, "count": 1}, {"text": "Takeda's extensive drug discovery", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.500584, "count": 1}, {"text": "genomic data", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.494596, "count": 1}, {"text": "new approaches", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.489763, "count": 1}, {"text": "new dietary approaches", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.481157, "count": 1}, {"text": "global health crisis of obesity", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.477114, "count": 1}, {"text": "psychiatric genetics", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.475852, "count": 1}, {"text": "industry desire", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.466367, "count": 1}, {"text": "site of America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460584, "count": 1}, {"text": "way kidney disease", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.460217, "count": 1}, {"text": "first English Thanksgiving", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.456967, "count": 1}]}, "extracted_metadata": {"sha1": "9f328fd16803a49d1fa0b677c1c876c7b73befd6", "filename": "1542993970438.zip-c63096963cc397685cdaa7abdfade560.xml", "file_type": "json"}, "title": "Wire | myScience / News"}, {"id": "NKz-SflnAFO0hOyMpOSU8LP0gDwXkS7ijoEgMiueqVjXTHFit2nnsWts_H3Ni-_f", "result_metadata": {"score": 25.859661}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [], "categories": [{"score": 0.999993, "label": "/news/national news"}, {"score": 0.999987, "label": "/business and industrial/business news"}, {"score": 0.952853, "label": "/news/international news"}], "relations": [], "keywords": [{"text": "Wire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.999596, "count": 1}, {"text": "News", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.950907, "count": 1}, {"text": "myScience", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.315024, "count": 1}]}, "crawl_date": "2018-11-23T17:26:10Z", "url": "https://www.myscience.org.uk/news/wire/eu_kommissar_informiert_sich_im_iccas_ueber_modulares_krankenhaus_fuer_den_katastrophenfall-2018-uni-leipzig", "host": "myscience.org.uk", "text": "Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T00:00:00Z", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Life Sciences", "relevance": 0.836245, "type": "Organization", "disambiguation": {"subtype": [], "name": "Life sciences", "dbpedia_resource": "http://dbpedia.org/resource/Life_sciences"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Earth Sciences - Life Sciences", "relevance": 0.675389, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.615765, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.494541, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cardiff University", "relevance": 0.479784, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "University of Nottingham", "relevance": 0.360988, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Nottingham", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Nottingham"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Universities of Bristol", "relevance": 0.339358, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Research Council", "relevance": 0.32913, "type": "Organization", "disambiguation": {"subtype": [], "name": "Medical Research Council (United Kingdom)", "dbpedia_resource": "http://dbpedia.org/resource/Medical_Research_Council_(United_Kingdom)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "James River", "relevance": 0.313604, "type": "GeographicFeature"}, {"count": 1, "sentiment": {"score": 0.665961, "label": "positive"}, "text": "Scottish government", "relevance": 0.304567, "type": "Organization", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Virginia", "relevance": 0.298225, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Virginia", "dbpedia_resource": "http://dbpedia.org/resource/Virginia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MRC", "relevance": 0.294256, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "America", "relevance": 0.288952, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tennessee", "relevance": 0.286911, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}], "sentiment": {"document": {"score": 0.284597, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Archaeologists from the Universities of Bristol and Tennessee", "keywords": [{"text": "Archaeologists"}, {"text": "Universities"}, {"text": "Bristol"}, {"text": "Tennessee"}], "entities": [{"type": "Organization", "text": "Universities of Bristol"}, {"type": "Location", "text": "Tennessee", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "object": {"text": "located evidence for the site of America's first English Thanksgiving on the James River in Virginia", "keywords": [{"text": "James River"}, {"text": "Thanksgiving"}, {"text": "evidence"}, {"text": "site"}], "entities": [{"type": "Location", "text": "America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "GeographicFeature", "text": "James River"}, {"type": "Location", "text": "Virginia", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Virginia", "dbpedia_resource": "http://dbpedia.org/resource/Virginia"}}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "Archaeologists from the Universities of Bristol and Tennessee", "keywords": [{"text": "Archaeologists"}, {"text": "Universities"}, {"text": "Bristol"}, {"text": "Tennessee"}], "entities": [{"type": "Organization", "text": "Universities of Bristol"}, {"type": "Location", "text": "Tennessee", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "object": {"text": "evidence", "keywords": [{"text": "evidence"}]}, "action": {"verb": {"text": "locate", "tense": "past"}, "text": "have located", "normalized": "have locate"}}, {"subject": {"text": "by the University of Nottingham", "keywords": [{"text": "Nottingham"}, {"text": "University"}], "entities": [{"type": "Organization", "text": "University of Nottingham", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "University of Nottingham", "dbpedia_resource": "http://dbpedia.org/resource/University_of_Nottingham"}}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "19.11.2018 A research team", "keywords": [{"text": "research team"}]}, "action": {"verb": {"text": "lead", "tense": "past"}, "text": "led", "normalized": "lead"}}, {"subject": {"text": "by the the Medical Research Council (MRC)", "keywords": [{"text": "MRC"}, {"text": "Medical Research Council"}], "entities": [{"type": "Organization", "text": "Medical Research Council", "disambiguation": {"subtype": [], "name": "Medical Research Council (United Kingdom)", "dbpedia_resource": "http://dbpedia.org/resource/Medical_Research_Council_(United_Kingdom)"}}, {"type": "Organization", "text": "MRC"}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "a grant", "keywords": [{"text": "grant"}]}, "action": {"verb": {"text": "award", "tense": "past"}, "text": "has been awarded", "normalized": "have be award"}}, {"subject": {"text": "the clinical translation of renal imaging and transform the way kidney disease", "keywords": [{"text": "way kidney disease"}, {"text": "renal imaging"}, {"text": "clinical translation"}]}, "sentence": " Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "object": {"text": "diagnosed"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "treating psychiatric disorders Cardiff University", "keywords": [{"text": "psychiatric disorders Cardiff"}], "entities": [{"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "sentence": " Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "object": {"text": "a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "drug discovery collaboration"}, {"text": "psychiatric disorders"}, {"text": "new approaches"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has formed", "normalized": "have form"}}, {"subject": {"text": "Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University", "keywords": [{"text": "psychiatric disorders Cardiff"}, {"text": "New approaches"}, {"text": "Earth Sciences"}, {"text": "Life Sciences"}], "entities": [{"type": "Organization", "text": "Earth Sciences - Life Sciences"}, {"type": "Organization", "text": "Cardiff University", "disambiguation": {"subtype": ["CollegeUniversity", "University"], "name": "Cardiff University", "dbpedia_resource": "http://dbpedia.org/resource/Cardiff_University"}}]}, "sentence": " Earth Sciences - Life Sciences - 19.11.2018 New approaches for treating psychiatric disorders Cardiff University has formed a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders.", "object": {"text": "a drug discovery collaboration with Takeda Pharmaceutical Company Limited (Takeda) to identify new approaches for treating schizophrenia and other psychiatric disorders", "keywords": [{"text": "Takeda Pharmaceutical Company"}, {"text": "drug discovery collaboration"}, {"text": "psychiatric disorders"}, {"text": "new approaches"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "form", "tense": "past"}, "text": "has formed", "normalized": "have form"}}, {"subject": {"text": "19.11.2018 With lowest cost green energy", "keywords": [{"text": "lowest cost green"}, {"text": "energy"}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "the future", "keywords": [{"text": "future"}]}, "action": {"verb": {"text": "consider", "tense": "past"}, "text": "considered", "normalized": "consider"}}, {"subject": {"text": "Computer Science / Telecom", "keywords": [{"text": "Telecom"}, {"text": "Science"}], "entities": []}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future", "keywords": [{"text": "onshore wind farms"}, {"text": "affordable wind power"}, {"text": "industry desire"}, {"text": "Scottish government"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "action": {"verb": {"text": "understand", "tense": "present"}, "text": "understanding", "normalized": "understand"}}, {"subject": {"text": "understanding how to \u2018repower' existing onshore wind farms", "keywords": [{"text": "onshore wind farms"}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "the Scottish government", "keywords": [{"text": "Scottish government"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "supports", "normalized": "support"}}, {"subject": {"text": "the Scottish government and industry", "keywords": [{"text": "Scottish government"}, {"text": "industry"}], "entities": [{"type": "Organization", "text": "Scottish government", "disambiguation": {"subtype": [], "name": "Scottish Government", "dbpedia_resource": "http://dbpedia.org/resource/Scottish_Government"}}]}, "sentence": " Computer Science / Telecom - 19.11.2018 With lowest cost green energy considered the future, understanding how to \u2018repower' existing onshore wind farms supports the Scottish government and industry desire to generate affordable wind power in the future.", "object": {"text": "affordable wind power", "keywords": [{"text": "affordable wind"}, {"text": "power"}], "entities": []}, "action": {"verb": {"text": "generate", "tense": "future"}, "text": "to generate", "normalized": "to generate"}}], "concepts": [{"text": "Genetics", "relevance": 0.96581, "dbpedia_resource": "http://dbpedia.org/resource/Genetics"}, {"text": "Pharmacology", "relevance": 0.956142, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Nutrition", "relevance": 0.878096, "dbpedia_resource": "http://dbpedia.org/resource/Nutrition"}, {"text": "Psychiatry", "relevance": 0.822709, "dbpedia_resource": "http://dbpedia.org/resource/Psychiatry"}, {"text": "Medicine", "relevance": 0.809112, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmaceutical industry", "relevance": 0.792414, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Wind farm", "relevance": 0.772576, "dbpedia_resource": "http://dbpedia.org/resource/Wind_farm"}, {"text": "Mental disorder", "relevance": 0.75695, "dbpedia_resource": "http://dbpedia.org/resource/Mental_disorder"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.745731, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Clinical trial", "relevance": 0.714706, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Wind power", "relevance": 0.709195, "dbpedia_resource": "http://dbpedia.org/resource/Wind_power"}, {"text": "Science", "relevance": 0.681694, "dbpedia_resource": "http://dbpedia.org/resource/Science"}, {"text": "Drug development", "relevance": 0.654584, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "Drug discovery", "relevance": 0.651247, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Gene", "relevance": 0.644384, "dbpedia_resource": "http://dbpedia.org/resource/Gene"}, {"text": "Wind", "relevance": 0.641573, "dbpedia_resource": "http://dbpedia.org/resource/Wind"}], "categories": [{"score": 0.912367, "label": "/science/medicine/medical research"}, {"score": 0.886062, "label": "/business and industrial/energy/renewable energy/wind energy"}, {"score": 0.847148, "label": "/health and fitness/disorders"}], "relations": [{"type": "locatedAt", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.865818, "arguments": [{"text": "site", "location": [92, 96], "entities": [{"type": "Location", "text": "site"}]}, {"text": "America", "location": [100, 107], "entities": [{"type": "GeopoliticalEntity", "text": "America", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.736589, "arguments": [{"text": "site", "location": [92, 96], "entities": [{"type": "Location", "text": "site"}]}, {"text": "English", "location": [116, 123], "entities": [{"type": "GeopoliticalEntity", "text": "English"}]}]}, {"type": "partOfMany", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.820195, "arguments": [{"text": "Thanksgiving", "location": [124, 136], "entities": [{"type": "Person", "text": "Thanksgiving"}]}, {"text": "English", "location": [116, 123], "entities": [{"type": "GeopoliticalEntity", "text": "English"}]}]}, {"type": "residesIn", "sentence": "Archaeologists from the Universities of Bristol and Tennessee have located evidence for the site of America's first English Thanksgiving on the James River in Virginia.", "score": 0.732729, "arguments": [{"text": "James River", "location": [144, 155], "entities": [{"type": "Person", "text": "James River"}]}, {"text": "Virginia", "location": [159, 167], "entities": [{"type": "GeopoliticalEntity", "text": "Virginia"}]}]}, {"type": "agentOf", "sentence": "Life Sciences - Music - 19.11.2018 A research team led by the University of Nottingham, has been awarded a grant by the the Medical Research Council (MRC) to enable the clinical translation of renal imaging and transform the way kidney disease is diagnosed and treated.", "score": 0.614282, "arguments": [{"text": "Medical Research Council", "location": [293, 317], "entities": [{"type": "Organization", "text": "Medical Research Council"}]}, {"text": "awarded", "location": [266, 273], "entities": [{"type": "EntertainmentAward", "text": "awarded"}]}]}, {"type": "agentOf", "sentence": "Life Sciences - Agronomy / Food Science - 19.11.2018 There is an urgent need for new dietary approaches and treatments to tackle the global health crisis of obesity in children and adults say experts.", "score": 0.69565, "arguments": [{"text": "adults", "location": [1144, 1150], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "say", "location": [1151, 1154], "entities": [{"type": "EventCommunication", "text": "say"}]}]}], "keywords": [{"text": "Life Sciences", "sentiment": {"score": -0.656557, "label": "negative"}, "relevance": 0.949396, "count": 4}, {"text": "Earth Sciences", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.840453, "count": 1}, {"text": "Universities of Bristol", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.672122, "count": 1}, {"text": "Food Science", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.648895, "count": 1}, {"text": "research team", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.64359, "count": 1}, {"text": "drug discovery collaboration", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.634426, "count": 1}, {"text": "Medical Research Council", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.601073, "count": 1}, {"text": "psychiatric disorders Cardiff University", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.596053, "count": 1}, {"text": "collaboration", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.590331, "count": 1}, {"text": "lowest cost", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.585581, "count": 1}, {"text": "green energy", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.581693, "count": 1}, {"text": "psychiatric disorders", "sentiment": {"score": -0.37013, "mixed": "1", "label": "negative"}, "relevance": 0.576386, "count": 1}, {"text": "New approaches", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.5751, "count": 1}, {"text": "urgent need", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.574867, "count": 1}, {"text": "Scottish government", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.570715, "count": 1}, {"text": "Takeda", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.564555, "count": 1}, {"text": "Takeda Pharmaceutical Company Limited", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.562587, "count": 1}, {"text": "Computer Science", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.559528, "count": 1}, {"text": "University of Nottingham", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.555807, "count": 1}, {"text": "Agronomy", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.553495, "count": 1}, {"text": "Archaeologists", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542134, "count": 1}, {"text": "Music", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.541937, "count": 1}, {"text": "Telecom", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.534746, "count": 1}, {"text": "grant", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.532393, "count": 1}, {"text": "genomics", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.528277, "count": 1}, {"text": "neuroscience", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.52763, "count": 1}, {"text": "James River", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527316, "count": 1}, {"text": "MRC", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.525936, "count": 1}, {"text": "Tennessee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525603, "count": 1}, {"text": "treatments", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.524143, "count": 1}, {"text": "evidence", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522629, "count": 1}, {"text": "University's large scale", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.521522, "count": 1}, {"text": "schizophrenia", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.51951, "count": 1}, {"text": "children", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.512786, "count": 1}, {"text": "onshore wind farms", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.510958, "count": 1}, {"text": "adults", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.510546, "count": 1}, {"text": "world-class expertise", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.50856, "count": 1}, {"text": "Virginia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507174, "count": 1}, {"text": "experts", "sentiment": {"score": 0.537436, "mixed": "1", "label": "positive"}, "relevance": 0.507174, "count": 1}, {"text": "clinical translation of renal imaging", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.504165, "count": 1}, {"text": "Takeda's extensive drug discovery", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.500584, "count": 1}, {"text": "genomic data", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.494596, "count": 1}, {"text": "new approaches", "sentiment": {"score": -0.873293, "label": "negative"}, "relevance": 0.489763, "count": 1}, {"text": "new dietary approaches", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.481157, "count": 1}, {"text": "global health crisis of obesity", "sentiment": {"score": -0.536538, "label": "negative"}, "relevance": 0.477114, "count": 1}, {"text": "psychiatric genetics", "sentiment": {"score": 0.610836, "label": "positive"}, "relevance": 0.475852, "count": 1}, {"text": "industry desire", "sentiment": {"score": 0.832713, "label": "positive"}, "relevance": 0.466367, "count": 1}, {"text": "site of America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.460584, "count": 1}, {"text": "way kidney disease", "sentiment": {"score": -0.478288, "label": "negative"}, "relevance": 0.460217, "count": 1}, {"text": "first English Thanksgiving", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.456967, "count": 1}]}, "extracted_metadata": {"sha1": "18cbef9363bc40db95dbe0d40a1a1006d1f8d4e7", "filename": "1542993970438.zip-92c530727ca7b5324bd49c9570b15b68.xml", "file_type": "json"}, "title": "Wire | myScience / News"}, {"id": "4AiX-9N6LKDL2f7AT26Q60T_OzgnzLDnpcGbTAr-ur2c1USSG-Gu7KaTmIRqtDb-", "result_metadata": {"score": 25.853092}, "author": "tanuj", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Facial Aesthetic Remodeling", "relevance": 0.33, "type": "PrintMedia"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Years in the future", "relevance": 0.862267, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}], "categories": [{"score": 0.678612, "label": "/style and fashion"}, {"score": 0.665492, "label": "/style and fashion/body art"}, {"score": 0.630514, "label": "/art and entertainment/visual art and design/art and craft supplies"}], "relations": [], "keywords": [{"text": "Steadfast Expansion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.5, "count": 1}]}, "crawl_date": "2018-11-23T15:13:37Z", "url": "https://www.findmarketresearch.org/2018/11/facial-aesthetic-remodeling-market-to-reflect-steadfast-expansion-during-2017-2025/", "host": "findmarketresearch.org", "text": "Facial Aesthetic Remodeling Market: Key Market Participants Some of the major apps for Facial Aesthetic Remodeling market constitute: Allergan, Galderma SA, Merck KGaA, Takeda Pharmaceutical Co Ltd, Cynosure Inc, Merz Aesthetics, Suneva Medical.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-23T09:38:00+05:00", "enriched_text": {"entities": [{"count": 16, "sentiment": {"score": 0.22809, "label": "positive"}, "text": "Facial Aesthetic Remodeling", "relevance": 0.903955, "type": "PrintMedia"}, {"count": 6, "sentiment": {"score": 0.502725, "label": "positive"}, "text": "Facial Aesthetic Remodeling Market", "relevance": 0.662816, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0.670452, "label": "positive"}, "text": "Facial Aesthetic Industry", "relevance": 0.233155, "type": "PrintMedia"}, {"count": 4, "sentiment": {"score": -0.135489, "label": "negative"}, "text": "Botox", "relevance": 0.0843987, "type": "HealthCondition", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}, {"count": 1, "sentiment": {"score": -0.250729, "label": "negative"}, "text": "skin discoloration", "relevance": 0.0747202, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0.290672, "label": "positive"}, "text": "Dermal Fillers", "relevance": 0.0639735, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "American Society of Plastic Surgeons", "relevance": 0.0593849, "type": "Organization", "disambiguation": {"subtype": [], "name": "American Society of Plastic Surgeons", "dbpedia_resource": "http://dbpedia.org/resource/American_Society_of_Plastic_Surgeons"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.0539562, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": -0.344037, "label": "negative"}, "text": "USA", "relevance": 0.0515366, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.594191, "label": "negative"}, "text": "North America", "relevance": 0.0493902, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.0475578, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.0472503, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck KGaA", "relevance": 0.0470768, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck KGaA", "dbpedia_resource": "http://dbpedia.org/resource/Merck_KGaA"}}, {"count": 1, "sentiment": {"score": -0.374807, "label": "negative"}, "text": "Galderma SA", "relevance": 0.046612, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.590552, "label": "positive"}, "text": "Merz Aesthetics", "relevance": 0.0432247, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.0431666, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.219436, "label": "negative"}, "text": "Asia-Pacific", "relevance": 0.0431008, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.219436, "label": "negative"}, "text": "Japan", "relevance": 0.0423001, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.0421222, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.0421116, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Suneva Medical", "relevance": 0.0420592, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.422693, "label": "positive"}, "text": "Cynosure Inc", "relevance": 0.0405563, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.0374431, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "four months", "relevance": 0.0374431, "type": "Quantity"}], "sentiment": {"document": {"score": 0.591221, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Facial Aesthetic Remodeling", "keywords": [{"text": "Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": "Facial Aesthetic Remodeling is a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face.", "object": {"text": "a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty", "keywords": [{"text": "cosmetic procedure"}, {"text": "comprehensive evaluation"}, {"text": "nature"}, {"text": "art"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a cosmetic procedure", "keywords": [{"text": "cosmetic procedure"}]}, "sentence": "Facial Aesthetic Remodeling is a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face.", "object": {"text": "a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face", "keywords": [{"text": "youthful appearance"}, {"text": "skin discoloration"}, {"text": "comprehensive evaluation"}, {"text": "human face"}], "entities": [{"type": "HealthCondition", "text": "skin discoloration"}]}, "action": {"verb": {"text": "entail", "tense": "present"}, "text": "entails", "normalized": "entail"}}, {"subject": {"text": "skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face", "keywords": [{"text": "youthful appearance"}, {"text": "skin discoloration"}, {"text": "human face"}, {"text": "skin laxity"}], "entities": [{"type": "HealthCondition", "text": "skin discoloration"}]}, "sentence": "Facial Aesthetic Remodeling is a cosmetic procedure entails a comprehensive evaluation of the nature of art, culture or beauty by altering the structure, style or form of something through the treatment of conditions including skin laxity, scars, excess fat, cellulite, wrinkles, moles, skin discoloration, etc. and restore the youthful appearance of the human face.", "object": {"text": "conditions", "keywords": [{"text": "conditions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "ageism in industrialized societies", "keywords": [{"text": "industrialized societies"}, {"text": "ageism"}]}, "sentence": " As ageism in industrialized societies is rapidly increasing, as one ages, facial aesthetic units gradually become distinct and lose due to a contour of the facial skeleton, the location of facial ligaments, differences in skin thickness and composition of subcutaneous tissue, so the demand for Facial Aesthetic Remodeling services is also emerging significantly.", "object": {"text": "rapidly increasing"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "facial aesthetic units", "keywords": [{"text": "facial aesthetic units"}]}, "sentence": " As ageism in industrialized societies is rapidly increasing, as one ages, facial aesthetic units gradually become distinct and lose due to a contour of the facial skeleton, the location of facial ligaments, differences in skin thickness and composition of subcutaneous tissue, so the demand for Facial Aesthetic Remodeling services is also emerging significantly.", "object": {"text": "distinct"}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "become", "normalized": "become"}}, {"subject": {"text": "surgical and nonsurgical procedures which provide a solution to the most advanced aesthetic enhancements and reshape the structure of the body to improve appearance and confidence", "keywords": [{"text": "advanced aesthetic enhancements"}, {"text": "nonsurgical procedures"}, {"text": "confidence"}, {"text": "appearance"}]}, "sentence": " Facial Aesthetic Remodeling includes surgical and nonsurgical procedures which provide a solution to the most advanced aesthetic enhancements and reshape the structure of the body to improve appearance and confidence.", "object": {"text": "Facial Aesthetic Remodeling", "keywords": [{"text": "Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "surgical and nonsurgical procedures", "keywords": [{"text": "nonsurgical procedures"}]}, "sentence": " Facial Aesthetic Remodeling includes surgical and nonsurgical procedures which provide a solution to the most advanced aesthetic enhancements and reshape the structure of the body to improve appearance and confidence.", "object": {"text": "a solution", "keywords": [{"text": "solution"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "surgical and nonsurgical procedures", "keywords": [{"text": "nonsurgical procedures"}]}, "sentence": " Facial Aesthetic Remodeling includes surgical and nonsurgical procedures which provide a solution to the most advanced aesthetic enhancements and reshape the structure of the body to improve appearance and confidence.", "object": {"text": "the structure of the body", "keywords": [{"text": "structure"}, {"text": "body"}]}, "action": {"verb": {"text": "reshape", "tense": "present"}, "text": "reshape", "normalized": "reshape"}}, {"subject": {"text": "Facial Aesthetic Remodeling", "keywords": [{"text": "Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "object": {"text": "dramatic benefits", "keywords": [{"text": "dramatic benefits"}]}, "action": {"verb": {"text": "provide", "tense": "future"}, "text": "to provide", "normalized": "to provide"}}, {"subject": {"text": "Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling ability"}, {"text": "dramatic benefits"}, {"text": "surgery"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "object": {"text": "made these procedures more accessible", "keywords": [{"text": "procedures"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling ability"}, {"text": "dramatic benefits"}, {"text": "surgery"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "object": {"text": "these procedures", "keywords": [{"text": "procedures"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "has made", "normalized": "have make"}}, {"subject": {"text": "caused something of a revolution", "keywords": [{"text": "revolution"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "their increasing popularity", "keywords": [{"text": "popularity"}]}, "sentence": " Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "object": {"text": "something of a revolution", "keywords": [{"text": "revolution"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "has caused", "normalized": "have cause"}}, {"subject": {"text": "The most popular procedure of Facial Aesthetic Remodeling", "keywords": [{"text": "Facial Aesthetic"}, {"text": "popular procedure"}, {"text": "Remodeling"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}, {"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "object": {"text": "Botox which injected into the Facial muscles without affecting it", "keywords": [{"text": "Facial muscles"}, {"text": "Botox"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Botox", "keywords": [{"text": "Botox"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}]}, "sentence": " The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "object": {"text": "into the Facial muscles", "keywords": [{"text": "Facial muscles"}]}, "action": {"verb": {"text": "inject", "tense": "past"}, "text": "injected", "normalized": "inject"}}, {"subject": {"text": "Botox", "keywords": [{"text": "Botox"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}]}, "sentence": " The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "object": {"text": "it"}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affecting", "normalized": "affect"}}, {"subject": {"text": "the skin", "keywords": [{"text": "skin"}]}, "sentence": " The most popular procedure of Facial Aesthetic Remodeling is Botox which injected into the Facial muscles without affecting it, and as a result, makes the skin smooth, the effect of Botox last for approximately for three to four months.", "object": {"text": "smooth, the effect of Botox last for approximately for three to four months", "keywords": [{"text": "Botox"}, {"text": "effect"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}, {"type": "Quantity", "text": "four months"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "14.2 million non-minimally invasive facial aesthetics treatments", "keywords": [{"text": "invasive facial aesthetics"}, {"text": "treatments"}]}, "sentence": " According to the American Society of Plastic Surgeons, 14.2 million non-minimally invasive facial aesthetics treatments were carried out in the USA in 2014, Botox was a clear favorite with over 6.3 million procedures followed by Dermal Fillers with 2.2 million procedures in total.", "object": {"text": "carried out in the USA", "keywords": [{"text": "USA"}], "entities": [{"type": "Location", "text": "USA", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "14.2 million non-minimally invasive facial aesthetics treatments", "keywords": [{"text": "invasive facial aesthetics"}, {"text": "treatments"}]}, "sentence": " According to the American Society of Plastic Surgeons, 14.2 million non-minimally invasive facial aesthetics treatments were carried out in the USA in 2014, Botox was a clear favorite with over 6.3 million procedures followed by Dermal Fillers with 2.2 million procedures in total.", "action": {"verb": {"text": "carry", "tense": "past"}, "text": "were carried", "normalized": "be carry"}}, {"subject": {"text": "Botox", "keywords": [{"text": "Botox"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}]}, "sentence": " According to the American Society of Plastic Surgeons, 14.2 million non-minimally invasive facial aesthetics treatments were carried out in the USA in 2014, Botox was a clear favorite with over 6.3 million procedures followed by Dermal Fillers with 2.2 million procedures in total.", "object": {"text": "a clear favorite with over 6.3 million procedures followed by Dermal Fillers with 2.2 million procedures in total", "keywords": [{"text": "Dermal Fillers"}, {"text": "clear favorite"}, {"text": "procedures"}], "entities": [{"type": "HealthCondition", "text": "Botox", "disambiguation": {"subtype": ["ChemicalCompound", "DiseaseCause", "MedicalTreatment", "Protein"], "name": "Botulinum toxin", "dbpedia_resource": "http://dbpedia.org/resource/Botulinum_toxin"}}, {"type": "Company", "text": "Dermal Fillers"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "The market of Facial Aesthetic Remodeling", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling"}, {"text": "market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}, {"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The market of Facial Aesthetic Remodeling have tremendous opportunity to grow since these procedures have the potential to provide high-technology skin care without involving significant discomfort.", "object": {"text": "tremendous opportunity to grow since these procedures have the potential to provide high-technology skin care without involving significant discomfort", "keywords": [{"text": "high-technology skin care"}, {"text": "significant discomfort"}, {"text": "tremendous opportunity"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "significant discomfort", "keywords": [{"text": "significant discomfort"}]}, "sentence": " The market of Facial Aesthetic Remodeling have tremendous opportunity to grow since these procedures have the potential to provide high-technology skin care without involving significant discomfort.", "object": {"text": "high-technology skin", "keywords": [{"text": "high-technology skin"}]}, "action": {"verb": {"text": "involve", "tense": "present"}, "text": "involving", "normalized": "involve"}}, {"subject": {"text": "The Desire to enhance the beauty and physical appearance", "keywords": [{"text": "physical appearance"}, {"text": "Desire"}, {"text": "beauty"}]}, "sentence": " The Desire to enhance the beauty and physical appearance among women with Increase in Awareness of the facial aesthetic procedures among the general public is the major factor that drives the Facial Aesthetic Remodeling Market .", "object": {"text": "the major factor that drives the Facial Aesthetic Remodeling Market", "keywords": [{"text": "Facial Aesthetic Remodeling"}, {"text": "major factor"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Facial Aesthetic Industry", "keywords": [{"text": "Industry"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Industry"}]}, "sentence": " The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period.", "object": {"text": "non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries", "keywords": [{"text": "non-invasive dermal fillers"}, {"text": "disposable income"}, {"text": "job opportunities"}, {"text": "rise"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "developing", "normalized": "develop"}}, {"subject": {"text": "non-invasive dermal fillers", "keywords": [{"text": "non-invasive dermal fillers"}]}, "sentence": " The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period.", "object": {"text": "to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period", "keywords": [{"text": "disposable income"}, {"text": "Facial Aesthetic"}, {"text": "market revenue"}, {"text": "forecast period"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "help", "normalized": "help"}}, {"subject": {"text": "non-invasive dermal fillers", "keywords": [{"text": "non-invasive dermal fillers"}]}, "sentence": " The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period.", "object": {"text": "aging"}, "action": {"verb": {"text": "address", "tense": "future"}, "text": "address", "normalized": "address"}}, {"subject": {"text": "the market revenue for Facial Aesthetic Remodeling", "keywords": [{"text": "Facial Aesthetic"}, {"text": "market revenue"}, {"text": "Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries is also expected to fuel the market revenue for Facial Aesthetic Remodeling over the forecast period.", "object": {"text": "The increase in efforts of Facial Aesthetic Industry on developing non-invasive dermal fillers that help to address aging more efficiently with the rise in disposable income due to increase in job opportunities in developing countries", "keywords": [{"text": "non-invasive dermal fillers"}, {"text": "Facial Aesthetic"}, {"text": "disposable income"}, {"text": "job opportunities"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Industry"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is also expected to fuel", "normalized": "be also expect to fuel"}}, {"subject": {"text": "certain side effects", "keywords": [{"text": "certain side effects"}]}, "sentence": " However, high expenses of treatments, and certain side effects associated with the procedures can hamper the growth of the Facial Aesthetic Remodeling market to some extent.", "object": {"text": "with the procedures", "keywords": [{"text": "procedures"}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "high expenses of treatments, and certain side effects associated with the procedures", "keywords": [{"text": "high expenses"}, {"text": "certain side effects"}, {"text": "treatments"}, {"text": "procedures"}]}, "sentence": " However, high expenses of treatments, and certain side effects associated with the procedures can hamper the growth of the Facial Aesthetic Remodeling market to some extent.", "object": {"text": "the growth of the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}]}, "action": {"verb": {"text": "hamper", "tense": "future"}, "text": "can hamper", "normalized": "can hamper"}}, {"subject": {"text": "Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " Facial Aesthetic Remodeling market is expected to extend at a noteworthy development rate crosswise over regions due to the rise in per capita expenditure on healthcare in the developed nations and increasing incidence of accidents.", "object": {"text": "at a noteworthy development rate crosswise over regions due to the rise in per capita expenditure on healthcare in the developed nations and increasing incidence of accidents", "keywords": [{"text": "noteworthy development rate"}, {"text": "capita expenditure"}, {"text": "incidence"}, {"text": "rise"}], "entities": []}, "action": {"verb": {"text": "extend", "tense": "future"}, "text": "is expected to extend", "normalized": "be expect to extend"}}, {"subject": {"text": "Continuous research by Pharmaceutical Companies", "keywords": [{"text": "Continuous research"}, {"text": "Pharmaceutical Companies"}], "entities": []}, "sentence": " Continuous research by Pharmaceutical Companies to develop certain methods for tightening loose skin to restore a youthful look as well as to expand their potential revenues which will lead to increase in the Facial Aesthetic Remodeling market.", "object": {"text": "certain methods for tightening loose skin to restore a youthful look as well as to expand their potential revenues which will lead to increase in the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}, {"text": "youthful look"}, {"text": "potential revenues"}, {"text": "loose skin"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "their potential revenues", "keywords": [{"text": "potential revenues"}]}, "sentence": " Continuous research by Pharmaceutical Companies to develop certain methods for tightening loose skin to restore a youthful look as well as to expand their potential revenues which will lead to increase in the Facial Aesthetic Remodeling market.", "object": {"text": "in the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling Market"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "to increase", "normalized": "to increase"}}, {"subject": {"text": "more areas", "keywords": [{"text": "areas"}]}, "sentence": " The rise in patients demand to treat more areas with the wider range of products and techniques can also drive the Facial Aesthetic Remodeling market that is expected to have a meteoric growth over a forecast period.", "object": {"text": "with the wider range of products", "keywords": [{"text": "wider range"}, {"text": "products"}]}, "action": {"verb": {"text": "treat", "tense": "future"}, "text": "demand to treat", "normalized": "demand to treat"}}, {"subject": {"text": "The rise in patients demand to treat more areas with the wider range of products and techniques", "keywords": [{"text": "wider range"}, {"text": "rise"}, {"text": "patients"}, {"text": "areas"}]}, "sentence": " The rise in patients demand to treat more areas with the wider range of products and techniques can also drive the Facial Aesthetic Remodeling market that is expected to have a meteoric growth over a forecast period.", "object": {"text": "the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "can also drive", "normalized": "can also drive"}}, {"subject": {"text": "the Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic Remodeling"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "sentence": " The rise in patients demand to treat more areas with the wider range of products and techniques can also drive the Facial Aesthetic Remodeling market that is expected to have a meteoric growth over a forecast period.", "object": {"text": "a meteoric growth", "keywords": [{"text": "meteoric growth"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "is expected to have", "normalized": "be expect to have"}}, {"subject": {"text": "it"}, "sentence": " A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "object": {"text": "been segmented into five broad regions", "keywords": [{"text": "broad regions"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Asia-Pacific", "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "object": {"text": "Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}]}, "action": {"verb": {"text": "exclude", "tense": "present"}, "text": "excluding", "normalized": "exclude"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America represents the largest Facial Aesthetic Remodeling market due to rising demand for the use of minimally invasive techniques and increasing population of elder people.", "object": {"text": "the largest Facial Aesthetic Remodeling market due to rising demand for the use of minimally invasive techniques and increasing population of elder people", "keywords": [{"text": "Facial Aesthetic Remodeling"}, {"text": "minimally invasive techniques"}, {"text": "elder people"}, {"text": "demand"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "Asia-Pacific regions", "keywords": [{"text": "Asia-Pacific regions"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "object": {"text": "upon to show high development rate in Facial Aesthetic Remodeling market", "keywords": [{"text": "Facial Aesthetic"}, {"text": "high development rate"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "rely", "tense": "past"}, "text": "are also relied", "normalized": "be also rely"}}, {"subject": {"text": "Asia-Pacific regions", "keywords": [{"text": "Asia-Pacific regions"}], "entities": [{"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "object": {"text": "high development rate in Facial Aesthetic Remodeling market", "keywords": [{"text": "high development rate"}, {"text": "Facial Aesthetic"}, {"text": "Remodeling market"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "show", "tense": "future"}, "text": "to show", "normalized": "to show"}}, {"subject": {"text": "high spending on latest technologies along with peer group encouragement", "keywords": [{"text": "peer group encouragement"}, {"text": "high spending"}, {"text": "latest technologies"}]}, "sentence": " Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "object": {"text": "the Facial Aesthetic Remodeling market growth", "keywords": [{"text": "Facial Aesthetic"}, {"text": "Remodeling market growth"}], "entities": [{"type": "PrintMedia", "text": "Facial Aesthetic Remodeling"}]}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "would propel", "normalized": "would propel"}}], "concepts": [{"text": "Skin", "relevance": 0.978081, "dbpedia_resource": "http://dbpedia.org/resource/Skin"}, {"text": "Dermis", "relevance": 0.853013, "dbpedia_resource": "http://dbpedia.org/resource/Dermis"}, {"text": "Beauty", "relevance": 0.76011, "dbpedia_resource": "http://dbpedia.org/resource/Beauty"}, {"text": "Plastic surgery", "relevance": 0.741182, "dbpedia_resource": "http://dbpedia.org/resource/Plastic_surgery"}, {"text": "Subcutaneous tissue", "relevance": 0.644348, "dbpedia_resource": "http://dbpedia.org/resource/Subcutaneous_tissue"}, {"text": "Aesthetics", "relevance": 0.588941, "dbpedia_resource": "http://dbpedia.org/resource/Aesthetics"}, {"text": "Invasive", "relevance": 0.507988, "dbpedia_resource": "http://dbpedia.org/resource/Invasive_(medical)"}, {"text": "Skin cancer", "relevance": 0.491058, "dbpedia_resource": "http://dbpedia.org/resource/Skin_cancer"}, {"text": "Facial muscles", "relevance": 0.483375, "dbpedia_resource": "http://dbpedia.org/resource/Facial_muscles"}, {"text": "Human skin color", "relevance": 0.482284, "dbpedia_resource": "http://dbpedia.org/resource/Human_skin_color"}, {"text": "Merck KGaA", "relevance": 0.468808, "dbpedia_resource": "http://dbpedia.org/resource/Merck_KGaA"}, {"text": "Economics", "relevance": 0.468175, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}], "categories": [{"score": 0.905093, "label": "/health and fitness"}, {"score": 0.752821, "label": "/health and fitness/therapy"}, {"score": 0.721524, "label": "/health and fitness/disorders"}], "relations": [{"type": "agentOf", "sentence": "Facial Aesthetic Remodeling ability to provide dramatic benefits without surgery has made these procedures more accessible and aided in their increasing popularity which has caused something of a revolution in the anti-ageing industry.", "score": 0.562709, "arguments": [{"text": "their", "location": [1085, 1090], "entities": [{"type": "Person", "text": "their"}]}, {"text": "revolution", "location": [1145, 1155], "entities": [{"type": "EventDemonstration", "text": "revolution"}]}]}, {"type": "employedBy", "sentence": "Facial Aesthetic Remodeling Market: Key Market Participants Some of the major apps for Facial Aesthetic Remodeling market constitute: Allergan, Galderma SA, Merck KGaA, Takeda Pharmaceutical Co Ltd, Cynosure Inc, Merz Aesthetics, Suneva Medical.", "score": 0.502033, "arguments": [{"text": "Participants", "location": [5057, 5069], "entities": [{"type": "Person", "text": "Participants"}]}, {"text": "Key Market", "location": [5046, 5056], "entities": [{"type": "Organization", "text": "Key Market", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Facial Aesthetic Remodeling Market: Segmentation The global market for Facial Aesthetic Remodeling is segmented on the basis of Procedure, End User, and geography:based on the Procedure, Facial Aesthetic Remodeling the following:,Surgical Procedure,Face and Head Procedure,Ear Surgery,Eyelid Surgery,Facelift,Facial Bone Contouring,Fat Grafting,Hair Transplantation,Rhinoplasty,Non- Surgical Procedure,Injectable,Botulinum Toxin,Calcium Hydroxylapatite,Hyaluronic Acid,Poly-L-Lactic Acid,Facial Rejuvenation,Dermal fillers,Laser skin resurfacing,chemical peels,Microdermabrasion,based on End User, Facial Aesthetic Remodeling the following:,Hospitals,Specialty Dermatology Clinics,Ambulatory Surgical Centers Facial Aesthetic Remodeling Market:", "score": 0.771877, "arguments": [{"text": "Bone Contouring", "location": [3128, 3143], "entities": [{"type": "Person", "text": "Bone Contouring"}]}, {"text": "Facial", "location": [3121, 3127], "entities": [{"type": "Organization", "text": "Facial Aesthetic Remodeling services"}]}]}, {"type": "employedBy", "sentence": "Facial Aesthetic Remodeling Market: Segmentation The global market for Facial Aesthetic Remodeling is segmented on the basis of Procedure, End User, and geography:based on the Procedure, Facial Aesthetic Remodeling the following:,Surgical Procedure,Face and Head Procedure,Ear Surgery,Eyelid Surgery,Facelift,Facial Bone Contouring,Fat Grafting,Hair Transplantation,Rhinoplasty,Non- Surgical Procedure,Injectable,Botulinum Toxin,Calcium Hydroxylapatite,Hyaluronic Acid,Poly-L-Lactic Acid,Facial Rejuvenation,Dermal fillers,Laser skin resurfacing,chemical peels,Microdermabrasion,based on End User, Facial Aesthetic Remodeling the following:,Hospitals,Specialty Dermatology Clinics,Ambulatory Surgical Centers Facial Aesthetic Remodeling Market:", "score": 0.450186, "arguments": [{"text": "Hyaluronic Acid", "location": [3265, 3280], "entities": [{"type": "Person", "text": "Hyaluronic Acid"}]}, {"text": "Poly-L-Lactic Acid", "location": [3281, 3299], "entities": [{"type": "Organization", "text": "Poly-L-Lactic Acid", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "Facial Aesthetic Remodeling Market: Region-wise Outlook A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "score": 0.452533, "arguments": [{"text": "Facial Aesthetic Remodeling Market", "location": [4261, 4295], "entities": [{"type": "Organization", "text": "Facial Aesthetic Remodeling services"}]}, {"text": "Region", "location": [4297, 4303], "entities": [{"type": "GeopoliticalEntity", "text": "Region"}]}]}, {"type": "locatedAt", "sentence": "Facial Aesthetic Remodeling Market: Region-wise Outlook A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "score": 0.489466, "arguments": [{"text": "regions", "location": [4428, 4435], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [4452, 4465], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Facial Aesthetic Remodeling Market: Region-wise Outlook A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "score": 0.490825, "arguments": [{"text": "regions", "location": [4428, 4435], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Europe", "location": [4467, 4473], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Facial Aesthetic Remodeling Market: Region-wise Outlook A geographic condition regarding for Facial Aesthetic Remodeling market, it has been segmented into five broad regions: North America, Latin America, Europe, Asia-Pacific excluding Japan, and the Middle East & Africa.", "score": 0.444189, "arguments": [{"text": "Asia-Pacific", "location": [4475, 4487], "entities": [{"type": "Person", "text": "Asia-Pacific"}]}, {"text": "Japan", "location": [4498, 4503], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "score": 0.462822, "arguments": [{"text": "Asia-Pacific", "location": [4716, 4728], "entities": [{"type": "Person", "text": "Asia-Pacific"}]}, {"text": "regions", "location": [4729, 4736], "entities": [{"type": "Location", "text": "regions"}]}]}, {"type": "partOf", "sentence": "Asia-Pacific regions are also relied upon to show high development rate in Facial Aesthetic Remodeling market because of increasing in research centers and high spending on latest technologies along with peer group encouragement that would propel the Facial Aesthetic Remodeling market growth.", "score": 0.411011, "arguments": [{"text": "peer group", "location": [4920, 4930], "entities": [{"type": "Organization", "text": "peer group", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Facial Aesthetic Remodeling", "location": [4791, 4818], "entities": [{"type": "Organization", "text": "Facial Aesthetic Remodeling services"}]}]}], "keywords": [{"text": "Facial Aesthetic Remodeling", "sentiment": {"score": 0.649204, "mixed": "1", "label": "positive"}, "relevance": 0.913011, "count": 3}, {"text": "facial aesthetic units", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.728525, "count": 1}, {"text": "cosmetic procedure", "sentiment": {"score": 0.783469, "label": "positive"}, "relevance": 0.669595, "count": 1}, {"text": "market of Facial Aesthetic Remodeling", "sentiment": {"score": 0.407506, "label": "positive"}, "relevance": 0.647677, "count": 1}, {"text": "contour of the facial skeleton", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.61558, "count": 1}, {"text": "Facial Aesthetic", "sentiment": {"score": 0.509856, "mixed": "1", "label": "positive"}, "relevance": 0.60627, "count": 14}, {"text": "North America", "sentiment": {"score": 0.340679, "mixed": "1", "label": "positive"}, "relevance": 0.589954, "count": 2}, {"text": "Market", "sentiment": {"score": -0.327169, "mixed": "1", "label": "negative"}, "relevance": 0.58632, "count": 5}, {"text": "Facial Aesthetic Remodeling ability", "sentiment": {"score": 0.772667, "label": "positive"}, "relevance": 0.584987, "count": 1}, {"text": "location of facial ligaments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577409, "count": 1}, {"text": "popular procedure of Facial Aesthetic Remodeling", "sentiment": {"score": 0.828386, "label": "positive"}, "relevance": 0.572415, "count": 1}, {"text": "procedures", "sentiment": {"score": 0.458323, "mixed": "1", "label": "positive"}, "relevance": 0.570772, "count": 5}, {"text": "nonsurgical procedures", "sentiment": {"score": 0.978904, "label": "positive"}, "relevance": 0.569513, "count": 1}, {"text": "Surgical Procedure", "sentiment": {"score": -0.687756, "label": "negative"}, "relevance": 0.55632, "count": 2}, {"text": "dermal facial fillers", "sentiment": {"score": 0.407764, "label": "positive"}, "relevance": 0.554572, "count": 1}, {"text": "major factor", "sentiment": {"score": 0.785389, "label": "positive"}, "relevance": 0.548926, "count": 1}, {"text": "skin laxity", "sentiment": {"score": 0.783469, "label": "positive"}, "relevance": 0.548895, "count": 1}, {"text": "Facial muscles", "sentiment": {"score": 0.828386, "label": "positive"}, "relevance": 0.548281, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0.879222, "label": "positive"}, "relevance": 0.547032, "count": 1}, {"text": "Facial Aesthetic Remodeling Market", "sentiment": {"score": 0.808629, "label": "positive"}, "relevance": 0.545919, "count": 1}, {"text": "high-technology skin care", "sentiment": {"score": 0.407506, "label": "positive"}, "relevance": 0.545147, "count": 1}, {"text": "treatment of conditions", "sentiment": {"score": 0.783469, "label": "positive"}, "relevance": 0.54484, "count": 1}, {"text": "Hyaluronic Acid", "sentiment": {"score": -0.687756, "label": "negative"}, "relevance": 0.540981, "count": 1}, {"text": "regions", "sentiment": {"score": -0.687756, "label": "negative"}, "relevance": 0.537743, "count": 1}, {"text": "treatment", "sentiment": {"score": 0.407764, "label": "positive"}, "relevance": 0.537605, "count": 1}, {"text": "general public", "sentiment": {"score": 0.785389, "label": "positive"}, "relevance": 0.537535, "count": 1}, {"text": "advanced aesthetic enhancements", "sentiment": {"score": 0.978904, "label": "positive"}, "relevance": 0.534672, "count": 1}, {"text": "increasing popularity", "sentiment": {"score": 0.772667, "label": "positive"}, "relevance": 0.533373, "count": 1}, {"text": "Pharmaceutical Companies", "sentiment": {"score": 0.892447, "label": "positive"}, "relevance": 0.533012, "count": 1}, {"text": "Botulinum Toxin", "sentiment": {"score": -0.687756, "label": "negative"}, "relevance": 0.532571, "count": 1}, {"text": "global market", "sentiment": {"score": -0.687756, "label": "negative"}, "relevance": 0.530536, "count": 1}, {"text": "research centers", "sentiment": {"score": 0.801404, "label": "positive"}, "relevance": 0.529145, "count": 1}, {"text": "disposable income", "sentiment": {"score": 0.830687, "label": "positive"}, "relevance": 0.527186, "count": 1}, {"text": "Merck KGaA", "sentiment": {"score": -0.756933, "label": "negative"}, "relevance": 0.526708, "count": 1}, {"text": "growth of the Facial Aesthetic Remodeling market", "sentiment": {"score": -0.517062, "label": "negative"}, "relevance": 0.526191, "count": 1}, {"text": "latest technologies", "sentiment": {"score": 0.801404, "label": "positive"}, "relevance": 0.526166, "count": 1}, {"text": "surgery", "sentiment": {"score": 0.772667, "label": "positive"}, "relevance": 0.525519, "count": 1}, {"text": "clear favorite", "sentiment": {"score": 0.364564, "label": "positive"}, "relevance": 0.524857, "count": 1}, {"text": "demand", "sentiment": {"score": -0.70135, "label": "negative"}, "relevance": 0.524115, "count": 2}, {"text": "invasive facial aesthetics treatments", "sentiment": {"score": 0.364564, "label": "positive"}, "relevance": 0.523328, "count": 1}, {"text": "physical appearance", "sentiment": {"score": 0.785389, "label": "positive"}, "relevance": 0.521571, "count": 1}, {"text": "skin", "sentiment": {"score": 0.828386, "label": "positive"}, "relevance": 0.521503, "count": 1}, {"text": "beauty", "sentiment": {"score": 0.78443, "label": "positive"}, "relevance": 0.520201, "count": 2}, {"text": "Awareness of the facial aesthetic procedures", "sentiment": {"score": 0.785389, "label": "positive"}, "relevance": 0.51988, "count": 1}, {"text": "ages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519845, "count": 1}, {"text": "Procedure", "sentiment": {"score": -0.687756, "label": "negative"}, "relevance": 0.519422, "count": 1}, {"text": "market", "sentiment": {"score": 0.375221, "mixed": "1", "label": "positive"}, "relevance": 0.519367, "count": 7}, {"text": "Desire", "sentiment": {"score": 0.785389, "label": "positive"}, "relevance": 0.518915, "count": 1}, {"text": "societies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51883, "count": 1}, {"text": "structure", "sentiment": {"score": 0.783469, "label": "positive"}, "relevance": 0.517615, "count": 1}]}, "extracted_metadata": {"sha1": "e9a734feea25e2f0ce6302dc18e54d5bfadc9bad", "filename": "1542986017252.zip-eee304d4eb4f718cb8f86439ad4aa606.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/facial-aesthetic-remodeling-market.asp", "https://www.persistencemarketresearch.com/samples/15190"], "title": "Facial Aesthetic Remodeling to Reflect Steadfast Expansion During 2017 \u2013 2025", "forum_title": "Research Insights | Find Market Research - Part 32"}, {"id": "TFrZ7833ATZr3sLfJg8Cnpc1xdRWMXw7uWKljyMLmaJDcjCG-1LOYrMDN-PZTiR_", "result_metadata": {"score": 25.78699}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dublin", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tokyo", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ricoh", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "LearnUpon & Ricoh", "entities": [{"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "sentence": "LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo", "object": {"text": "companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}], "concepts": [{"text": "Ch\u016b\u014d, Tokyo", "relevance": 0.851497, "dbpedia_resource": "http://dbpedia.org/resource/Ch\u016b\u014d,_Tokyo"}, {"text": "Minato, Tokyo", "relevance": 0.837625, "dbpedia_resource": "http://dbpedia.org/resource/Minato,_Tokyo"}, {"text": "Global city", "relevance": 0.795914, "dbpedia_resource": "http://dbpedia.org/resource/Global_city"}], "categories": [{"score": 0.821679, "label": "/technology and computing/consumer electronics/camera and photo equipment"}, {"score": 0.697297, "label": "/technology and computing/consumer electronics/camera and photo equipment/cameras and camcorders/cameras"}, {"score": 0.63704, "label": "/business and industrial/company"}], "relations": [{"type": "locatedAt", "sentence": "LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo", "score": 0.346495, "arguments": [{"text": "companies", "location": [24, 33], "entities": [{"type": "Organization", "text": "companies"}]}, {"text": "Dublin", "location": [72, 78], "entities": [{"type": "GeopoliticalEntity", "text": "Dublin"}]}]}], "keywords": [{"text": "Ricoh", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.918196, "count": 1}, {"text": "LearnUpon", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.842923, "count": 1}, {"text": "companies of the year", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.839489, "count": 1}, {"text": "Dublin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.687236, "count": 1}, {"text": "Tokyo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.656845, "count": 1}, {"text": "separate ceremonies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.61135, "count": 1}]}, "crawl_date": "2018-11-24T06:33:58Z", "url": "https://insideireland.ie/2018/11/24/learnupon-ricoh-named-companies-of-the-year-in-separate-ceremonies-in-dublin-and-tokyo/", "host": "insideireland.ie", "text": "Previous winners of the Ireland Japan Business Awards include Fujitsu Laboratories, SMBC, Takeda Pharmaceutical and Corvil.", "country": "IE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-24T05:51:00Z", "enriched_text": {"entities": [{"count": 17, "sentiment": {"score": 0.620681, "label": "positive"}, "text": "Technology Ireland Company", "relevance": 0.91138, "type": "Company"}, {"count": 8, "sentiment": {"score": 0.519607, "label": "positive"}, "text": "Ricoh Ireland", "relevance": 0.444537, "type": "Company"}, {"count": 8, "sentiment": {"score": 0.46957, "label": "positive"}, "text": "Ricoh", "relevance": 0.440482, "type": "Company", "disambiguation": {"subtype": ["SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ireland Japan Chamber of Commerce", "relevance": 0.403699, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Technology Ireland Person", "relevance": 0.337, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ireland Japan Business", "relevance": 0.332063, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0.64125, "label": "positive"}, "text": "Technology Ireland", "relevance": 0.292737, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0.48173, "label": "positive"}, "text": "Fidelity Investments Ireland", "relevance": 0.288008, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Technology Ireland", "relevance": 0.284647, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ireland Japan Business", "relevance": 0.250165, "type": "Company"}, {"count": 4, "sentiment": {"score": 0.741537, "label": "positive"}, "text": "Dublin", "relevance": 0.219628, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bank of Ireland", "relevance": 0.207947, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.609113, "label": "positive"}, "text": "Technology \u2022 Technology Innovation", "relevance": 0.203701, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0.616053, "label": "positive"}, "text": "ThinScale Technology", "relevance": 0.199039, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Enterprise Ireland", "relevance": 0.197445, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.331743, "label": "positive"}, "text": "Noel King", "relevance": 0.159229, "type": "Person", "disambiguation": {"subtype": [], "name": "Noel King", "dbpedia_resource": "http://dbpedia.org/resource/Noel_King"}}, {"count": 2, "sentiment": {"score": 0.217065, "label": "positive"}, "text": "Coolest Projects", "relevance": 0.145531, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.503751, "label": "positive"}, "text": "Aspire Technology", "relevance": 0.142182, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.741537, "label": "positive"}, "text": "Tokyo", "relevance": 0.138158, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "WomenInTech Company Initiative", "relevance": 0.13211, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Corporate Executive Vice President", "relevance": 0.131719, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.217065, "label": "positive"}, "text": "Emerging Company", "relevance": 0.128197, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Akira Oyama", "relevance": 0.127333, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vhi Healthcare", "relevance": 0.123538, "type": "Company", "disambiguation": {"subtype": [], "name": "Vhi Healthcare", "dbpedia_resource": "http://dbpedia.org/resource/Vhi_Healthcare"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mansion House", "relevance": 0.123125, "type": "Facility", "disambiguation": {"subtype": ["Location", "Building"], "name": "Mansion House, Dublin", "dbpedia_resource": "http://dbpedia.org/resource/Mansion_House,_Dublin"}}, {"count": 1, "sentiment": {"score": 0.427319, "label": "positive"}, "text": "TripAdvisor", "relevance": 0.122867, "type": "Company", "disambiguation": {"subtype": ["Website", "Brand"], "name": "TripAdvisor", "dbpedia_resource": "http://dbpedia.org/resource/TripAdvisor"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.122041, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Allstate", "relevance": 0.11966, "type": "Company", "disambiguation": {"subtype": [], "name": "Allstate", "dbpedia_resource": "http://dbpedia.org/resource/Allstate"}}, {"count": 1, "sentiment": {"score": 0.356103, "label": "positive"}, "text": "Phil Keoghan", "relevance": 0.119048, "type": "Person", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "TVPersonality", "TVProducer", "TVActor"], "name": "Phil Keoghan", "dbpedia_resource": "http://dbpedia.org/resource/Phil_Keoghan"}}, {"count": 1, "sentiment": {"score": 0.64125, "label": "positive"}, "text": "Una Fitzpatrick", "relevance": 0.117943, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Irish Government", "relevance": 0.115751, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Belgrade", "relevance": 0.115148, "type": "Location", "disambiguation": {"subtype": ["PlaceWithNeighborhoods", "FilmProducer", "City"], "name": "Belgrade", "dbpedia_resource": "http://dbpedia.org/resource/Belgrade"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ADAPT Centre", "relevance": 0.113596, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "co-founder", "relevance": 0.110589, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Herman Miller", "relevance": 0.110587, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.216259, "label": "positive"}, "text": "Temple Street Children\u2019s Hospital", "relevance": 0.109577, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0.64125, "label": "positive"}, "text": "Director", "relevance": 0.108487, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.10804, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0.57512, "label": "positive"}, "text": "Philadelphia", "relevance": 0.107128, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicBiddingCity", "PlaceWithNeighborhoods", "AirportOperator", "City"], "name": "Philadelphia", "dbpedia_resource": "http://dbpedia.org/resource/Philadelphia"}}, {"count": 1, "sentiment": {"score": 0.216259, "label": "positive"}, "text": "FoodCloud", "relevance": 0.106778, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.105733, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Country"], "name": "Northern Ireland", "dbpedia_resource": "http://dbpedia.org/resource/Northern_Ireland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Paul Gilsenan", "relevance": 0.104982, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President", "relevance": 0.104075, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Corvil", "relevance": 0.103243, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0.347884, "label": "positive"}, "text": "Paul Kavanagh", "relevance": 0.102978, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CEO", "relevance": 0.0996468, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.403168, "label": "positive"}, "text": "Sydney", "relevance": 0.0917642, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Fujitsu Laboratories", "relevance": 0.0908499, "type": "Company"}], "sentiment": {"document": {"score": 0.887203, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "LearnUpon & Ricoh"}, "sentence": "Informing, illuminating and intelligent debate LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo", "object": {"text": "illuminating and intelligent debate", "keywords": [{"text": "intelligent debate"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "action": {"verb": {"text": "Informing", "tense": "present"}, "text": "Informing", "normalized": "Informing"}}, {"subject": {"text": "LearnUpon & Ricoh"}, "sentence": "Informing, illuminating and intelligent debate LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo", "object": {"text": "companies of the year", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "Irish tech company LearnUpon", "keywords": [{"text": "Irish tech company"}, {"text": "LearnUpon"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " Irish tech company LearnUpon has been named Technology Ireland Company of the Year, while Ricoh also won Company of the Year at the Ireland Japan Business Awards.", "object": {"text": "of the Year"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has been named", "normalized": "have be name"}}, {"subject": {"text": "Irish tech company LearnUpon", "keywords": [{"text": "Irish tech company"}, {"text": "LearnUpon"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " Irish tech company LearnUpon has been named Technology Ireland Company of the Year, while Ricoh also won Company of the Year at the Ireland Japan Business Awards.", "object": {"text": "named Technology Ireland Company of the Year", "keywords": [{"text": "Technology Ireland Company"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Ricoh", "entities": [{"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "sentence": " Irish tech company LearnUpon has been named Technology Ireland Company of the Year, while Ricoh also won Company of the Year at the Ireland Japan Business Awards.", "object": {"text": "Company of the Year", "keywords": [{"text": "Company"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "action": {"verb": {"text": "win", "tense": "past"}, "text": "won", "normalized": "win"}}, {"subject": {"text": "LearnUpon", "keywords": [{"text": "LearnUpon"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " Headquartered in Dublin, LearnUpon employs over 70 people and has offices in Belgrade, Sydney, and Philadelphia.", "object": {"text": "over 70 people", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "employ", "tense": "present"}, "text": "employs", "normalized": "employ"}}, {"subject": {"text": "offices", "keywords": [{"text": "offices"}]}, "sentence": " Headquartered in Dublin, LearnUpon employs over 70 people and has offices in Belgrade, Sydney, and Philadelphia.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " The company is a Learning Management System that \u2018helps organisations to train their employees, partners, and customers\u2019.", "object": {"text": "a Learning Management System that \u2018helps organisations to train their employees, partners, and customers\u2019", "keywords": [{"text": "Learning Management"}, {"text": "organisations"}, {"text": "employees"}, {"text": "partners"}], "entities": [{"type": "JobTitle", "text": "Technology Ireland Company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a Learning Management System", "keywords": [{"text": "Learning Management"}], "entities": [{"type": "JobTitle", "text": "Technology Ireland Company"}]}, "sentence": " The company is a Learning Management System that \u2018helps organisations to train their employees, partners, and customers\u2019.", "object": {"text": "organisations", "keywords": [{"text": "organisations"}]}, "action": {"verb": {"text": "\u2018helps", "tense": "present"}, "text": "\u2018helps", "normalized": "\u2018helps"}}, {"subject": {"text": "Technology Ireland", "keywords": [{"text": "Technology Ireland"}], "entities": [{"type": "Company", "text": "Technology Ireland"}]}, "sentence": " Technology Ireland is the Ibec group that represents the sector", "object": {"text": "the Ibec group that represents the sector", "keywords": [{"text": "Ibec group"}, {"text": "sector"}], "entities": [{"type": "Company", "text": "Technology Ireland"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the Ibec group", "keywords": [{"text": "Ibec group"}], "entities": [{"type": "Company", "text": "Technology Ireland"}]}, "sentence": " Technology Ireland is the Ibec group that represents the sector", "object": {"text": "the sector", "keywords": [{"text": "sector"}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "Established in 2012, LearnUpon", "keywords": [{"text": "LearnUpon"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " \u201cEstablished in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "object": {"text": "one of the fastest growing LMSs", "keywords": [{"text": "fastest growing LMSs"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "LMSs", "keywords": [{"text": "LMSs"}]}, "sentence": " \u201cEstablished in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "object": {"text": "on the market", "keywords": [{"text": "market"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "TripAdvisor, Twilio, Vauxhall, Herman Miller, PING", "keywords": [{"text": "Herman Miller"}, {"text": "TripAdvisor"}, {"text": "Vauxhall"}, {"text": "PING"}], "entities": [{"type": "Company", "text": "TripAdvisor", "disambiguation": {"subtype": ["Website", "Brand"], "name": "TripAdvisor", "dbpedia_resource": "http://dbpedia.org/resource/TripAdvisor"}}, {"type": "Person", "text": "Herman Miller"}]}, "sentence": " \u201cEstablished in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "object": {"text": "1,000 clients", "keywords": [{"text": "clients"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "LearnUpon", "keywords": [{"text": "LearnUpon"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " LearnUpon\u2019s rapid growth has been driven off designing and developing a platform that is quick to setup, easy to use for customers and a platform which can be effectively and rapidly scaled globally\u201d.", "object": {"text": "rapid growth", "keywords": [{"text": "rapid growth"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "LearnUpon\u2019s rapid growth", "keywords": [{"text": "rapid growth"}, {"text": "LearnUpon"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " LearnUpon\u2019s rapid growth has been driven off designing and developing a platform that is quick to setup, easy to use for customers and a platform which can be effectively and rapidly scaled globally\u201d.", "object": {"text": "been driven off designing", "keywords": [{"text": "designing"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "LearnUpon\u2019s rapid growth", "keywords": [{"text": "rapid growth"}, {"text": "LearnUpon"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " LearnUpon\u2019s rapid growth has been driven off designing and developing a platform that is quick to setup, easy to use for customers and a platform which can be effectively and rapidly scaled globally\u201d.", "object": {"text": "driven"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "a platform", "keywords": [{"text": "platform"}]}, "sentence": " LearnUpon\u2019s rapid growth has been driven off designing and developing a platform that is quick to setup, easy to use for customers and a platform which can be effectively and rapidly scaled globally\u201d.", "object": {"text": "quick to setup"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Centre", "keywords": [{"text": "Centre"}]}, "sentence": " \u2022 Technology Ireland Company of the Year: LearnUpon \u2022 Technology Ireland Person of the Year: Noel King, co-founder Coolest Projects \u2022 Emerging Company of the Year: ThinScale Technology \u2022 Outstanding Achievement in International Growth: Aspire Technology \u2022 Technology Innovation of the Year: Siren \u2022 Digital Technology Services Project of the Year: GeoPal \u2022 WomenInTech Company Initiative of the Year: Fidelity Investments Ireland \u2022 Excellence in Talent Development: eShopWorld \u2022 Outstanding Academic Achievement of the Year: ADAPT Centre Via Twitter", "object": {"text": "Via Twitter", "keywords": [{"text": "Twitter"}]}, "action": {"verb": {"text": "ADAPT", "tense": "present"}, "text": "ADAPT", "normalized": "ADAPT"}}, {"subject": {"text": "Noel King, co-founder of Coolest Projects", "keywords": [{"text": "Coolest Projects"}, {"text": "Noel King"}, {"text": "co-founder"}], "entities": [{"type": "Person", "text": "Noel King", "disambiguation": {"subtype": ["Person"], "name": "Noel King", "dbpedia_resource": "http://dbpedia.org/resource/Noel_King"}}, {"type": "JobTitle", "text": "co-founder"}, {"type": "Company", "text": "Coolest Projects"}]}, "sentence": " Noel King, co-founder of Coolest Projects was named Technology Ireland Person of the Year 2018.", "object": {"text": "named Technology Ireland Person of the Year 2018", "keywords": [{"text": "Technology Ireland Person"}], "entities": [{"type": "JobTitle", "text": "Technology Ireland Person"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Noel King, co-founder of Coolest Projects", "keywords": [{"text": "Coolest Projects"}, {"text": "Noel King"}, {"text": "co-founder"}], "entities": [{"type": "Person", "text": "Noel King", "disambiguation": {"subtype": ["Person"], "name": "Noel King", "dbpedia_resource": "http://dbpedia.org/resource/Noel_King"}}, {"type": "JobTitle", "text": "co-founder"}, {"type": "Company", "text": "Coolest Projects"}]}, "sentence": " Noel King, co-founder of Coolest Projects was named Technology Ireland Person of the Year 2018.", "object": {"text": "Technology Ireland Person of the Year 2018", "keywords": [{"text": "Technology Ireland Person"}], "entities": [{"type": "JobTitle", "text": "Technology Ireland Person"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "was named", "normalized": "be name"}}, {"subject": {"text": "by platinum sponsors Vhi Healthcare, and gold sponsors Bank of Ireland, ByrneWallace and Enterprise Ireland", "keywords": [{"text": "platinum sponsors Vhi"}, {"text": "gold sponsors"}, {"text": "Enterprise Ireland"}, {"text": "Healthcare"}], "entities": [{"type": "Company", "text": "Vhi Healthcare", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Vhi Healthcare", "dbpedia_resource": "http://dbpedia.org/resource/Vhi_Healthcare"}}, {"type": "Company", "text": "Bank of Ireland"}, {"type": "Company", "text": "Enterprise Ireland"}]}, "sentence": " The event was supported by platinum sponsors Vhi Healthcare, and gold sponsors Bank of Ireland, ByrneWallace and Enterprise Ireland.", "object": {"text": "The event", "keywords": [{"text": "event"}]}, "action": {"verb": {"text": "support", "tense": "past"}, "text": "was supported", "normalized": "be support"}}, {"subject": {"text": "Ricoh", "entities": [{"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "sentence": " Ricoh named Company of the Year by Ireland Japan Chamber of Commerce", "object": {"text": "Company", "keywords": [{"text": "Company"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "Ricoh", "entities": [{"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "sentence": " Ricoh also announced on 23 November that it has been named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo.", "object": {"text": "that it has been named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo", "keywords": [{"text": "Ireland Japan Business"}, {"text": "Tokyo"}, {"text": "Company"}, {"text": "Awards"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}, {"type": "Organization", "text": "Ireland Japan Business"}, {"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "it"}, "sentence": " Ricoh also announced on 23 November that it has been named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo.", "object": {"text": "named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo", "keywords": [{"text": "Ireland Japan Business"}, {"text": "Tokyo"}, {"text": "Company"}, {"text": "Awards"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}, {"type": "Organization", "text": "Ireland Japan Business"}, {"type": "Location", "text": "Tokyo", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the Ireland Japan Business Awards 2018", "keywords": [{"text": "Ireland Japan Business"}, {"text": "Awards"}], "entities": [{"type": "Organization", "text": "Ireland Japan Business"}]}, "sentence": " Ricoh also announced on 23 November that it has been named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo.", "action": {"verb": {"text": "hold", "tense": "past"}, "text": "held", "normalized": "hold"}}, {"subject": {"text": "by the Ireland Japan Chamber of Commerce", "keywords": [{"text": "Ireland Japan Chamber"}, {"text": "Commerce"}], "entities": [{"type": "Organization", "text": "Ireland Japan Chamber of Commerce"}]}, "sentence": " Hosted by the Ireland Japan Chamber of Commerce, the annual awards recognise the companies making \u2018outstanding contributions to Ireland-Japan business relations\u2019.", "object": {"text": "the annual awards", "keywords": [{"text": "annual awards"}]}, "action": {"verb": {"text": "Hosted", "tense": "past"}, "text": "Hosted", "normalized": "Hosted"}}, {"subject": {"text": "the annual awards", "keywords": [{"text": "annual awards"}]}, "sentence": " Hosted by the Ireland Japan Chamber of Commerce, the annual awards recognise the companies making \u2018outstanding contributions to Ireland-Japan business relations\u2019.", "object": {"text": "the companies making \u2018outstanding contributions to Ireland-Japan business relations\u2019", "keywords": [{"text": "Ireland-Japan business relations"}, {"text": "contributions"}, {"text": "companies"}]}, "action": {"verb": {"text": "recognise", "tense": "present"}, "text": "recognise", "normalized": "recognise"}}, {"subject": {"text": "Phil Keoghan, CEO, Ricoh Ireland & UK,", "keywords": [{"text": "Ricoh Ireland"}, {"text": "Phil Keoghan"}, {"text": "CEO"}, {"text": "UK"}], "entities": [{"type": "Person", "text": "Phil Keoghan", "disambiguation": {"subtype": ["AwardNominee", "AwardWinner", "TVPersonality", "TVProducer", "TVActor"], "name": "Phil Keoghan", "dbpedia_resource": "http://dbpedia.org/resource/Phil_Keoghan"}}, {"type": "JobTitle", "text": "CEO"}, {"type": "Company", "text": "Ricoh Ireland"}, {"type": "Location", "text": "UK", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Country"], "name": "Northern Ireland", "dbpedia_resource": "http://dbpedia.org/resource/Northern_Ireland"}}]}, "sentence": " Phil Keoghan, CEO, Ricoh Ireland & UK, said the award \u2018is a tremendous honour\u2019 for the team in Ricoh Ireland.", "object": {"text": "the award \u2018is a tremendous honour\u2019 for the team in Ricoh Ireland", "keywords": [{"text": "tremendous honour"}, {"text": "Ricoh Ireland"}, {"text": "award"}, {"text": "team"}], "entities": [{"type": "Company", "text": "Ricoh Ireland", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "Ricoh\u2019s relationship with Ireland", "keywords": [{"text": "Ricoh"}, {"text": "relationship"}, {"text": "Ireland"}], "entities": [{"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}, {"type": "Location", "text": "Ricoh Ireland", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "Republic of Ireland", "dbpedia_resource": "http://dbpedia.org/resource/Republic_of_Ireland"}}]}, "sentence": " \u201cRicoh\u2019s relationship with Ireland started in the 1980s when 34 Irish graduates joined Ricoh in Japan through the Irish Government\u2019s F\u00c1S training scheme.", "action": {"verb": {"text": "start", "tense": "past"}, "text": "started", "normalized": "start"}}, {"subject": {"text": "34 Irish graduates", "keywords": [{"text": "Irish graduates"}]}, "sentence": " \u201cRicoh\u2019s relationship with Ireland started in the 1980s when 34 Irish graduates joined Ricoh in Japan through the Irish Government\u2019s F\u00c1S training scheme.", "object": {"text": "Ricoh", "entities": [{"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "action": {"verb": {"text": "join", "tense": "past"}, "text": "joined", "normalized": "join"}}, {"subject": {"text": "Ricoh Ireland", "keywords": [{"text": "Ricoh Ireland"}], "entities": [{"type": "Company", "text": "Ricoh Ireland"}]}, "sentence": " Almost four decades on, Ricoh Ireland has become a shining example of the positive impact that global organisations can have on the communities in which they operate.\u201d Pictured are (L \u2013 R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan", "object": {"text": "become a shining example of the positive impact that global organisations can have on the communities in which they operate.\u201d Pictured are (L \u2013 R) Paul Gilsenan", "keywords": [{"text": "Paul Gilsenan"}, {"text": "global organisations"}, {"text": "positive impact"}, {"text": "Pictured"}], "entities": [{"type": "Person", "text": "Paul Gilsenan"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "Ricoh Ireland", "keywords": [{"text": "Ricoh Ireland"}], "entities": [{"type": "Company", "text": "Ricoh Ireland"}]}, "sentence": " Almost four decades on, Ricoh Ireland has become a shining example of the positive impact that global organisations can have on the communities in which they operate.\u201d Pictured are (L \u2013 R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan", "object": {"text": "a shining example of the positive impact that global organisations can have on the communities in which they operate.\u201d Pictured are (L \u2013 R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan", "keywords": [{"text": "Executive Vice President"}, {"text": "H.E. Paul Kavanagh"}, {"text": "Ireland Japan Chamber"}, {"text": "Akira Oyama"}], "entities": [{"type": "Person", "text": "Paul Gilsenan"}, {"type": "JobTitle", "text": "President"}, {"type": "Organization", "text": "Ireland Japan Chamber of Commerce"}, {"type": "Person", "text": "Akira Oyama"}, {"type": "JobTitle", "text": "Corporate Executive Vice President"}, {"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}, {"type": "Person", "text": "Paul Kavanagh"}, {"type": "Location", "text": "Ricoh Ireland", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Country"], "name": "Republic of Ireland", "dbpedia_resource": "http://dbpedia.org/resource/Republic_of_Ireland"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "become", "tense": "past"}, "text": "has become", "normalized": "have become"}}, {"subject": {"text": "global organisations", "keywords": [{"text": "global organisations"}]}, "sentence": " Almost four decades on, Ricoh Ireland has become a shining example of the positive impact that global organisations can have on the communities in which they operate.\u201d Pictured are (L \u2013 R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan", "object": {"text": "the positive impact", "keywords": [{"text": "positive impact"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "can have", "normalized": "can have"}}, {"subject": {"text": "Akira Oyama, Corporate Executive Vice President, Ricoh", "keywords": [{"text": "Executive Vice President"}, {"text": "Akira Oyama"}], "entities": [{"type": "Person", "text": "Akira Oyama"}, {"type": "JobTitle", "text": "Corporate Executive Vice President"}, {"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "sentence": " Akira Oyama, Corporate Executive Vice President, Ricoh said the award reflects the \u2018wealth of symbiotic economic opportunity that lies in Irish-Japanese relations\u2019.", "object": {"text": "the award reflects the \u2018wealth of symbiotic economic opportunity that lies in Irish-Japanese relations\u2019", "keywords": [{"text": "symbiotic economic opportunity"}, {"text": "Irish-Japanese relations"}, {"text": "award"}, {"text": "\u2018wealth"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "the \u2018wealth of symbiotic economic opportunity that lies in Irish-Japanese relations\u2019", "keywords": [{"text": "symbiotic economic opportunity"}, {"text": "Irish-Japanese relations"}, {"text": "\u2018wealth"}]}, "sentence": " Akira Oyama, Corporate Executive Vice President, Ricoh said the award reflects the \u2018wealth of symbiotic economic opportunity that lies in Irish-Japanese relations\u2019.", "object": {"text": "the award", "keywords": [{"text": "award"}]}, "action": {"verb": {"text": "reflect", "tense": "present"}, "text": "reflects", "normalized": "reflect"}}, {"subject": {"text": "symbiotic economic opportunity", "keywords": [{"text": "symbiotic economic opportunity"}]}, "sentence": " Akira Oyama, Corporate Executive Vice President, Ricoh said the award reflects the \u2018wealth of symbiotic economic opportunity that lies in Irish-Japanese relations\u2019.", "object": {"text": "in Irish-Japanese relations\u2019", "keywords": [{"text": "Irish-Japanese relations"}]}, "action": {"verb": {"text": "lie", "tense": "present"}, "text": "lies", "normalized": "lie"}}, {"subject": {"text": "Ricoh Ireland", "keywords": [{"text": "Ricoh Ireland"}], "entities": [{"type": "Company", "text": "Ricoh Ireland"}]}, "sentence": " \u201cSince the 1980s Ricoh Ireland has gone from strength to strength and as it grows, so too does the local team\u2019s impact on the Irish economy\u2026 Ricoh Ireland is a great success story for us \u2013 on both sides of the globe \u2013 and we will continue to invest in our Irish team as the market grows.\u201d", "action": {"verb": {"text": "go", "tense": "past"}, "text": "has gone", "normalized": "have go"}}, {"subject": {"text": "the Irish economy\u2026 Ricoh Ireland", "keywords": [{"text": "Irish economy\u2026 Ricoh"}], "entities": [{"type": "Company", "text": "Ricoh Ireland"}]}, "sentence": " \u201cSince the 1980s Ricoh Ireland has gone from strength to strength and as it grows, so too does the local team\u2019s impact on the Irish economy\u2026 Ricoh Ireland is a great success story for us \u2013 on both sides of the globe \u2013 and we will continue to invest in our Irish team as the market grows.\u201d", "object": {"text": "a great success story for us \u2013 on both sides of the globe \u2013", "keywords": [{"text": "great success story"}, {"text": "sides"}, {"text": "globe"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "we"}, "sentence": " \u201cSince the 1980s Ricoh Ireland has gone from strength to strength and as it grows, so too does the local team\u2019s impact on the Irish economy\u2026 Ricoh Ireland is a great success story for us \u2013 on both sides of the globe \u2013 and we will continue to invest in our Irish team as the market grows.\u201d", "object": {"text": "to invest in our Irish team as the market grows", "keywords": [{"text": "Irish team"}, {"text": "market"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "continue", "normalized": "continue"}}, {"subject": {"text": "we"}, "sentence": " \u201cSince the 1980s Ricoh Ireland has gone from strength to strength and as it grows, so too does the local team\u2019s impact on the Irish economy\u2026 Ricoh Ireland is a great success story for us \u2013 on both sides of the globe \u2013 and we will continue to invest in our Irish team as the market grows.\u201d", "action": {"verb": {"text": "invest", "tense": "future"}, "text": "will continue to invest", "normalized": "will continue to invest"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " In February 2017, the company opened its new Irish HQ in Dublin on the back of a \u20ac6.5m investment, and the company hopes to double its workforce to 190 by 2020 and increase revenues to \u20ac32m in the same period.", "object": {"text": "its new Irish HQ", "keywords": [{"text": "new Irish HQ"}]}, "action": {"verb": {"text": "open", "tense": "past"}, "text": "opened", "normalized": "open"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " In February 2017, the company opened its new Irish HQ in Dublin on the back of a \u20ac6.5m investment, and the company hopes to double its workforce to 190 by 2020 and increase revenues to \u20ac32m in the same period.", "object": {"text": "to double its workforce to 190 by 2020 and increase revenues to \u20ac32m in the same period", "keywords": [{"text": "revenues"}, {"text": "workforce"}, {"text": "period"}], "entities": [{"type": "Quantity", "text": "32m"}]}, "action": {"verb": {"text": "hope", "tense": "present"}, "text": "hopes", "normalized": "hope"}}, {"subject": {"text": "the company", "keywords": [{"text": "company"}], "entities": [{"type": "Company", "text": "Technology Ireland Company"}]}, "sentence": " In February 2017, the company opened its new Irish HQ in Dublin on the back of a \u20ac6.5m investment, and the company hopes to double its workforce to 190 by 2020 and increase revenues to \u20ac32m in the same period.", "object": {"text": "its workforce", "keywords": [{"text": "workforce"}]}, "action": {"verb": {"text": "double", "tense": "future"}, "text": "hopes to double", "normalized": "hope to double"}}, {"subject": {"text": "Ricoh Ireland", "keywords": [{"text": "Ricoh Ireland"}], "entities": [{"type": "Company", "text": "Ricoh Ireland"}]}, "sentence": " Ricoh Ireland said in 2017, it donated \u20ac175,000 worth of \u2018managed document services technology\u2019 to Temple Street Children\u2019s Hospital and \u20ac30,000 worth of collaborative technologies to FoodCloud, the platform that allows businesses to donate unsold fresh food produce to local charities.", "object": {"text": "it donated \u20ac175,000 worth of \u2018managed document services technology\u2019 to Temple Street Children\u2019s Hospital and \u20ac30,000 worth of collaborative technologies to FoodCloud, the platform that allows businesses to donate unsold fresh food produce to local charities", "keywords": [{"text": "unsold fresh food"}, {"text": "document services technology"}, {"text": "Temple Street Children"}, {"text": "collaborative technologies"}], "entities": [{"type": "Facility", "text": "Temple Street Children\u2019s Hospital"}, {"type": "Company", "text": "FoodCloud"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "it"}, "sentence": " Ricoh Ireland said in 2017, it donated \u20ac175,000 worth of \u2018managed document services technology\u2019 to Temple Street Children\u2019s Hospital and \u20ac30,000 worth of collaborative technologies to FoodCloud, the platform that allows businesses to donate unsold fresh food produce to local charities.", "object": {"text": "document services technology", "keywords": [{"text": "document services technology"}]}, "action": {"verb": {"text": "\u2018managed", "tense": "past"}, "text": "\u2018managed", "normalized": "\u2018managed"}}, {"subject": {"text": "the platform", "keywords": [{"text": "platform"}]}, "sentence": " Ricoh Ireland said in 2017, it donated \u20ac175,000 worth of \u2018managed document services technology\u2019 to Temple Street Children\u2019s Hospital and \u20ac30,000 worth of collaborative technologies to FoodCloud, the platform that allows businesses to donate unsold fresh food produce to local charities.", "object": {"text": "businesses to donate unsold fresh food produce to local charities", "keywords": [{"text": "unsold fresh food"}, {"text": "local charities"}, {"text": "businesses"}]}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allows", "normalized": "allow"}}, {"subject": {"text": "Ricoh", "entities": [{"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "sentence": " Ricoh also works with Irish-based organisations to help them use technology to increase productivity and drive innovation.", "object": {"text": "them use technology to increase productivity and drive innovation", "keywords": [{"text": "drive innovation"}, {"text": "productivity"}, {"text": "technology"}]}, "action": {"verb": {"text": "help", "tense": "future"}, "text": "to help", "normalized": "to help"}}, {"subject": {"text": "Ricoh", "entities": [{"type": "Company", "text": "Ricoh", "disambiguation": {"subtype": ["Organization", "SoftwareDeveloper"], "name": "Ricoh", "dbpedia_resource": "http://dbpedia.org/resource/Ricoh"}}]}, "sentence": " Ricoh also works with Irish-based organisations to help them use technology to increase productivity and drive innovation.", "object": {"text": "productivity and drive innovation", "keywords": [{"text": "drive innovation"}, {"text": "productivity"}]}, "action": {"verb": {"text": "increase", "tense": "future"}, "text": "to increase", "normalized": "to increase"}}, {"subject": {"text": "Fujitsu Laboratories, SMBC, Takeda Pharmaceutical and Corvil.Elsewhere", "keywords": [{"text": "Fujitsu Laboratories"}, {"text": "Takeda Pharmaceutical"}, {"text": "SMBC"}, {"text": "Corvil.Elsewhere"}], "entities": [{"type": "Company", "text": "Fujitsu Laboratories"}, {"type": "Company", "text": "Takeda Pharmaceutical", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Location", "text": "Corvil", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Previous winners of the Ireland Japan Business Awards include Fujitsu Laboratories, SMBC, Takeda Pharmaceutical and Corvil.", "object": {"text": "Previous winners of the Ireland Japan Business Awards", "keywords": [{"text": "Previous winners"}, {"text": "Ireland Japan Business"}, {"text": "Awards"}], "entities": [{"type": "Company", "text": "Ireland Japan Business"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Republic of Ireland", "relevance": 0.974356, "dbpedia_resource": "http://dbpedia.org/resource/Republic_of_Ireland"}, {"text": "Dublin", "relevance": 0.802406, "dbpedia_resource": "http://dbpedia.org/resource/Dublin"}, {"text": "Vice president", "relevance": 0.769385, "dbpedia_resource": "http://dbpedia.org/resource/Vice_president"}, {"text": "Technology", "relevance": 0.620407, "dbpedia_resource": "http://dbpedia.org/resource/Technology"}, {"text": "Taoiseach", "relevance": 0.59701, "dbpedia_resource": "http://dbpedia.org/resource/Taoiseach"}, {"text": "Financial services in the Republic of Ireland", "relevance": 0.564178, "dbpedia_resource": "http://dbpedia.org/resource/Financial_services_in_the_Republic_of_Ireland"}, {"text": "Award", "relevance": 0.530647, "dbpedia_resource": "http://dbpedia.org/resource/Award"}, {"text": "Constitution of Ireland", "relevance": 0.527923, "dbpedia_resource": "http://dbpedia.org/resource/Constitution_of_Ireland"}, {"text": "Government of Ireland", "relevance": 0.518684, "dbpedia_resource": "http://dbpedia.org/resource/Government_of_Ireland"}, {"text": "Irish people", "relevance": 0.516392, "dbpedia_resource": "http://dbpedia.org/resource/Irish_people"}, {"text": "Irish language", "relevance": 0.513918, "dbpedia_resource": "http://dbpedia.org/resource/Irish_language"}, {"text": "Ireland", "relevance": 0.511838, "dbpedia_resource": "http://dbpedia.org/resource/Ireland"}, {"text": "Chambers of commerce", "relevance": 0.507264, "dbpedia_resource": "http://dbpedia.org/resource/Chambers_of_commerce"}, {"text": "President of Ireland", "relevance": 0.505406, "dbpedia_resource": "http://dbpedia.org/resource/President_of_Ireland"}, {"text": "Irish Free State", "relevance": 0.497518, "dbpedia_resource": "http://dbpedia.org/resource/Irish_Free_State"}, {"text": "Entrepreneurship", "relevance": 0.494501, "dbpedia_resource": "http://dbpedia.org/resource/Entrepreneurship"}, {"text": "Economy of the Republic of Ireland", "relevance": 0.491314, "dbpedia_resource": "http://dbpedia.org/resource/Economy_of_the_Republic_of_Ireland"}, {"text": "Politics of the Republic of Ireland", "relevance": 0.485028, "dbpedia_resource": "http://dbpedia.org/resource/Politics_of_the_Republic_of_Ireland"}, {"text": "Oireachtas", "relevance": 0.481358, "dbpedia_resource": "http://dbpedia.org/resource/Oireachtas"}], "categories": [{"score": 0.791741, "label": "/business and industrial"}, {"score": 0.748461, "label": "/technology and computing/enterprise technology"}, {"score": 0.74666, "label": "/finance/financial news"}], "relations": [{"type": "partOf", "sentence": "Informing, illuminating and intelligent debate LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo Irish tech company LearnUpon has been named Technology Ireland Company of the Year, while Ricoh also won Company of the Year at the Ireland Japan Business Awards.", "score": 0.447725, "arguments": [{"text": "companies", "location": [71, 80], "entities": [{"type": "Organization", "text": "companies"}]}, {"text": "Ricoh", "location": [59, 64], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}]}, {"type": "locatedAt", "sentence": "Technology Ireland Industry Awards LearnUpon was named Company of the Year at the 26th Annual Technology Ireland Industry Awards on Friday 23 November 2018, in the Round Room of the Mansion House, Dublin.", "score": 0.98472, "arguments": [{"text": "Mansion House", "location": [481, 494], "entities": [{"type": "Facility", "text": "Mansion House"}]}, {"text": "Dublin", "location": [496, 502], "entities": [{"type": "GeopoliticalEntity", "text": "Irish HQ"}]}]}, {"type": "locatedAt", "sentence": "Headquartered in Dublin, LearnUpon employs over 70 people and has offices in Belgrade, Sydney, and Philadelphia.", "score": 0.95556, "arguments": [{"text": "Dublin", "location": [521, 527], "entities": [{"type": "GeopoliticalEntity", "text": "Irish HQ"}]}, {"text": "LearnUpon", "location": [529, 538], "entities": [{"type": "GeopoliticalEntity", "text": "LearnUpon"}]}]}, {"type": "populationOf", "sentence": "Headquartered in Dublin, LearnUpon employs over 70 people and has offices in Belgrade, Sydney, and Philadelphia.", "score": 0.624815, "arguments": [{"text": "over 70", "location": [547, 554], "entities": [{"type": "Cardinal", "text": "over 70"}]}, {"text": "LearnUpon", "location": [529, 538], "entities": [{"type": "GeopoliticalEntity", "text": "LearnUpon"}]}]}, {"type": "affectedBy", "sentence": "Headquartered in Dublin, LearnUpon employs over 70 people and has offices in Belgrade, Sydney, and Philadelphia.", "score": 0.951628, "arguments": [{"text": "people", "location": [555, 561], "entities": [{"type": "Person", "text": "people"}]}, {"text": "employs", "location": [539, 546], "entities": [{"type": "EventPersonnel", "text": "employs"}]}]}, {"type": "basedIn", "sentence": "Headquartered in Dublin, LearnUpon employs over 70 people and has offices in Belgrade, Sydney, and Philadelphia.", "score": 0.547649, "arguments": [{"text": "offices", "location": [570, 577], "entities": [{"type": "Organization", "text": "offices"}]}, {"text": "Belgrade", "location": [581, 589], "entities": [{"type": "GeopoliticalEntity", "text": "Belgrade"}]}]}, {"type": "locatedAt", "sentence": "Headquartered in Dublin, LearnUpon employs over 70 people and has offices in Belgrade, Sydney, and Philadelphia.", "score": 0.710107, "arguments": [{"text": "Belgrade", "location": [581, 589], "entities": [{"type": "GeopoliticalEntity", "text": "Belgrade"}]}, {"text": "Sydney", "location": [591, 597], "entities": [{"type": "GeopoliticalEntity", "text": "Sydney"}]}]}, {"type": "parentOf", "sentence": "The company is a Learning Management System that \u02bbhelps organisations to train their employees, partners, and customers'.", "score": 0.228435, "arguments": [{"text": "their", "location": [696, 701], "entities": [{"type": "Person", "text": "customers"}]}, {"text": "employees", "location": [702, 711], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "agentOf", "sentence": "Technology Ireland is the Ibec group that represents the sector Presenting the Award, Technology Ireland Director Una Fitzpatrick said: \"Established in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "score": 0.564137, "arguments": [{"text": "Technology Ireland", "location": [739, 757], "entities": [{"type": "Organization", "text": "Technology Ireland Company"}]}, {"text": "said", "location": [869, 873], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "awardedTo", "sentence": "Technology Ireland is the Ibec group that represents the sector Presenting the Award, Technology Ireland Director Una Fitzpatrick said: \"Established in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "score": 0.570154, "arguments": [{"text": "Award", "location": [818, 823], "entities": [{"type": "EntertainmentAward", "text": "Award"}]}, {"text": "Ibec group", "location": [765, 775], "entities": [{"type": "Organization", "text": "Ibec group"}]}]}, {"type": "employedBy", "sentence": "Technology Ireland is the Ibec group that represents the sector Presenting the Award, Technology Ireland Director Una Fitzpatrick said: \"Established in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "score": 0.445748, "arguments": [{"text": "Director", "location": [844, 852], "entities": [{"type": "Person", "text": "Una Fitzpatrick"}]}, {"text": "Technology Ireland", "location": [825, 843], "entities": [{"type": "Organization", "text": "Technology Ireland Company"}]}]}, {"type": "basedIn", "sentence": "Informing, illuminating and intelligent debate LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo Irish tech company LearnUpon has been named Technology Ireland Company of the Year, while Ricoh also won Company of the Year at the Ireland Japan Business Awards.", "score": 0.66434, "arguments": [{"text": "tech company", "location": [142, 154], "entities": [{"type": "Organization", "text": "LearnUpon", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Dublin", "location": [119, 125], "entities": [{"type": "GeopoliticalEntity", "text": "Irish HQ"}]}]}, {"type": "basedIn", "sentence": "\" In February 2017, the company opened its new Irish HQ in Dublin on the back of a \u20a06.5m investment, and the company hopes to double its workforce to 190 by 2020 and increase revenues to \u20a032m in the same period.", "score": 0.391887, "arguments": [{"text": "its", "location": [3702, 3705], "entities": [{"type": "Organization", "text": "LearnUpon", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Irish HQ", "location": [3710, 3718], "entities": [{"type": "GeopoliticalEntity", "text": "Irish HQ"}]}]}, {"type": "agentOf", "sentence": "Technology Ireland is the Ibec group that represents the sector Presenting the Award, Technology Ireland Director Una Fitzpatrick said: \"Established in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "score": 0.487324, "arguments": [{"text": "Una Fitzpatrick", "location": [853, 868], "entities": [{"type": "Person", "text": "Una Fitzpatrick"}]}, {"text": "said", "location": [869, 873], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "timeOf", "sentence": "Technology Ireland is the Ibec group that represents the sector Presenting the Award, Technology Ireland Director Una Fitzpatrick said: \"Established in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "score": 0.643098, "arguments": [{"text": "2012", "location": [891, 895], "entities": [{"type": "Date", "text": "2012"}]}, {"text": "said", "location": [869, 873], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "Technology Ireland is the Ibec group that represents the sector Presenting the Award, Technology Ireland Director Una Fitzpatrick said: \"Established in 2012, LearnUpon is one of the fastest growing LMSs on the market today with over 1,000 clients including TripAdvisor, Twilio, Vauxhall, Herman Miller, PING, and Allstate.", "score": 0.614044, "arguments": [{"text": "clients", "location": [978, 985], "entities": [{"type": "Person", "text": "clients"}]}, {"text": "TripAdvisor", "location": [996, 1007], "entities": [{"type": "Organization", "text": "TripAdvisor", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Full list of winners \u00b7 Technology Ireland Company of the Year: LearnUpon \u00b7 Technology Ireland Person of the Year: Noel King, co-founder Coolest Projects \u00b7 Emerging Company of the Year: ThinScale Technology \u00b7 Outstanding Achievement in International Growth: Aspire Technology \u00b7 Technology Innovation of the Year: Siren \u00b7 Digital Technology Services Project of the Year: GeoPal \u00b7 WomenInTech Company Initiative of the Year: Fidelity Investments Ireland \u00b7 Excellence in Talent Development: eShopWorld \u00b7 Outstanding Academic Achievement of the Year: ADAPT Centre Via Twitter Noel King, co-founder of Coolest Projects was named Technology Ireland Person of the Year 2018.", "score": 0.463488, "arguments": [{"text": "Technology \u2022 Outstanding Achievement", "location": [1458, 1494], "entities": [{"type": "Organization", "text": "Technology \u2022 Outstanding Achievement"}]}, {"text": "International Growth", "location": [1498, 1518], "entities": [{"type": "Organization", "text": "International Growth"}]}]}, {"type": "timeOf", "sentence": "Full list of winners \u00b7 Technology Ireland Company of the Year: LearnUpon \u00b7 Technology Ireland Person of the Year: Noel King, co-founder Coolest Projects \u00b7 Emerging Company of the Year: ThinScale Technology \u00b7 Outstanding Achievement in International Growth: Aspire Technology \u00b7 Technology Innovation of the Year: Siren \u00b7 Digital Technology Services Project of the Year: GeoPal \u00b7 WomenInTech Company Initiative of the Year: Fidelity Investments Ireland \u00b7 Excellence in Talent Development: eShopWorld \u00b7 Outstanding Academic Achievement of the Year: ADAPT Centre Via Twitter Noel King, co-founder of Coolest Projects was named Technology Ireland Person of the Year 2018.", "score": 0.706705, "arguments": [{"text": "Year", "location": [1569, 1573], "entities": [{"type": "Date", "text": "Year"}]}, {"text": "Siren", "location": [1575, 1580], "entities": [{"type": "TitleWork", "text": "Siren"}]}]}, {"type": "partOf", "sentence": "Full list of winners \u00b7 Technology Ireland Company of the Year: LearnUpon \u00b7 Technology Ireland Person of the Year: Noel King, co-founder Coolest Projects \u00b7 Emerging Company of the Year: ThinScale Technology \u00b7 Outstanding Achievement in International Growth: Aspire Technology \u00b7 Technology Innovation of the Year: Siren \u00b7 Digital Technology Services Project of the Year: GeoPal \u00b7 WomenInTech Company Initiative of the Year: Fidelity Investments Ireland \u00b7 Excellence in Talent Development: eShopWorld \u00b7 Outstanding Academic Achievement of the Year: ADAPT Centre Via Twitter Noel King, co-founder of Coolest Projects was named Technology Ireland Person of the Year 2018.", "score": 0.462545, "arguments": [{"text": "Excellence", "location": [1716, 1726], "entities": [{"type": "Organization", "text": "Excellence", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Fidelity Investments Ireland", "location": [1685, 1713], "entities": [{"type": "Organization", "text": "Fidelity Investments Ireland", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "awardedTo", "sentence": "Other award winners on the night were ThinScale Technology, Aspire Technology, Siren, GeoPal, Fidelity Investments Ireland, eShopWorld and ADAPT Centre.", "score": 0.734077, "arguments": [{"text": "award", "location": [1936, 1941], "entities": [{"type": "EntertainmentAward", "text": "Award"}]}, {"text": "winners", "location": [1942, 1949], "entities": [{"type": "Person", "text": "winners"}]}]}, {"type": "locatedAt", "sentence": "Other award winners on the night were ThinScale Technology, Aspire Technology, Siren, GeoPal, Fidelity Investments Ireland, eShopWorld and ADAPT Centre.", "score": 0.924613, "arguments": [{"text": "Siren", "location": [2009, 2014], "entities": [{"type": "GeopoliticalEntity", "text": "Siren"}]}, {"text": "GeoPal", "location": [2016, 2022], "entities": [{"type": "GeopoliticalEntity", "text": "GeoPal"}]}]}, {"type": "employedBy", "sentence": "The event was supported by platinum sponsors Vhi Healthcare, and gold sponsors Bank of Ireland, ByrneWallace and Enterprise Ireland.", "score": 0.64153, "arguments": [{"text": "Vhi Healthcare", "location": [2128, 2142], "entities": [{"type": "Person", "text": "Vhi Healthcare"}]}, {"text": "sponsors", "location": [2119, 2127], "entities": [{"type": "GeopoliticalEntity", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}]}, {"type": "agentOf", "sentence": "Ricoh named Company of the Year by Ireland Japan Chamber of Commerce Ricoh also announced on 23 November that it has been named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo.", "score": 0.559866, "arguments": [{"text": "Ricoh", "location": [2216, 2221], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}, {"text": "announced", "location": [2296, 2305], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "basedIn", "sentence": "Informing, illuminating and intelligent debate LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo Irish tech company LearnUpon has been named Technology Ireland Company of the Year, while Ricoh also won Company of the Year at the Ireland Japan Business Awards.", "score": 0.891632, "arguments": [{"text": "tech company", "location": [142, 154], "entities": [{"type": "Organization", "text": "LearnUpon", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Tokyo\nIrish", "location": [130, 141], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo\nIrish"}]}]}, {"type": "timeOf", "sentence": "Ricoh named Company of the Year by Ireland Japan Chamber of Commerce Ricoh also announced on 23 November that it has been named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo.", "score": 0.965052, "arguments": [{"text": "23 November", "location": [2309, 2320], "entities": [{"type": "Date", "text": "23 November"}]}, {"text": "announced", "location": [2296, 2305], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "basedIn", "sentence": "Ricoh named Company of the Year by Ireland Japan Chamber of Commerce Ricoh also announced on 23 November that it has been named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo.", "score": 0.460339, "arguments": [{"text": "Ireland Japan Business Awards", "location": [2371, 2400], "entities": [{"type": "Organization", "text": "Ireland Japan Business Awards"}]}, {"text": "Tokyo", "location": [2414, 2419], "entities": [{"type": "GeopoliticalEntity", "text": "Tokyo\nIrish"}]}]}, {"type": "basedIn", "sentence": "Hosted by the Ireland Japan Chamber of Commerce, the annual awards recognise the companies making \u02bboutstanding contributions to Ireland-Japan business relations'.", "score": 0.859852, "arguments": [{"text": "business", "location": [2563, 2571], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Japan", "location": [2557, 2562], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Phil Keoghan, CEO, Ricoh Ireland & UK, said the award \u02bbis a tremendous honour' for the team in Ricoh Ireland.", "score": 0.479085, "arguments": [{"text": "team", "location": [2671, 2675], "entities": [{"type": "Organization", "text": "team", "disambiguation": {"subtype": ["Sports"]}}]}, {"text": "Ricoh Ireland", "location": [2679, 2692], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}]}, {"type": "partOfMany", "sentence": "\"Ricoh's relationship with Ireland started in the 1980s when 34 Irish graduates joined Ricoh in Japan through the Irish Government's F\u00c1S training scheme.", "score": 0.906719, "arguments": [{"text": "graduates", "location": [2764, 2773], "entities": [{"type": "Person", "text": "graduates"}]}, {"text": "Irish", "location": [2758, 2763], "entities": [{"type": "GeopoliticalEntity", "text": "Irish", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "\"Ricoh's relationship with Ireland started in the 1980s when 34 Irish graduates joined Ricoh in Japan through the Irish Government's F\u00c1S training scheme.", "score": 0.511742, "arguments": [{"text": "Ricoh", "location": [2781, 2786], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}, {"text": "Japan", "location": [2790, 2795], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "Almost four decades on, Ricoh Ireland has become a shining example of the positive impact that global organisations can have on the communities in which they operate.", "score": 0.3831, "arguments": [{"text": "they", "location": [3001, 3005], "entities": [{"type": "Person", "text": "they"}]}, {"text": "which", "location": [2995, 3000], "entities": [{"type": "Location", "text": "communities"}]}]}, {"type": "managerOf", "sentence": "\" Pictured are (L - R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan Akira Oyama, Corporate Executive Vice President, Ricoh said the award reflects the \u02bbwealth of symbiotic economic opportunity that lies in Irish-Japanese relations'.", "score": 0.65331, "arguments": [{"text": "President", "location": [3052, 3061], "entities": [{"type": "Person", "text": "Paul Gilsenan"}]}, {"text": "Ireland Japan Chamber of Commerce", "location": [3065, 3098], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}]}, {"type": "employedBy", "sentence": "\" Pictured are (L - R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan Akira Oyama, Corporate Executive Vice President, Ricoh said the award reflects the \u02bbwealth of symbiotic economic opportunity that lies in Irish-Japanese relations'.", "score": 0.659933, "arguments": [{"text": "Paul Kavanagh", "location": [3165, 3178], "entities": [{"type": "Person", "text": "Paul Kavanagh"}]}, {"text": "H.E.", "location": [3160, 3164], "entities": [{"type": "Organization", "text": "H.E."}]}]}, {"type": "managerOf", "sentence": "\" Pictured are (L - R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan Akira Oyama, Corporate Executive Vice President, Ricoh said the award reflects the \u02bbwealth of symbiotic economic opportunity that lies in Irish-Japanese relations'.", "score": 0.490599, "arguments": [{"text": "Ambassador", "location": [3180, 3190], "entities": [{"type": "Person", "text": "Paul Kavanagh"}]}, {"text": "Ireland", "location": [3194, 3201], "entities": [{"type": "GeopoliticalEntity", "text": "Ireland Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Informing, illuminating and intelligent debate LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo Irish tech company LearnUpon has been named Technology Ireland Company of the Year, while Ricoh also won Company of the Year at the Ireland Japan Business Awards.", "score": 0.248123, "arguments": [{"text": "Company", "location": [241, 248], "entities": [{"type": "Organization", "text": "Technology Ireland Company"}]}, {"text": "Ricoh", "location": [226, 231], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}]}, {"type": "partOf", "sentence": "Ricoh named Company of the Year by Ireland Japan Chamber of Commerce Ricoh also announced on 23 November that it has been named Company of the Year at the Ireland Japan Business Awards 2018 held in Tokyo.", "score": 0.455473, "arguments": [{"text": "Company", "location": [2228, 2235], "entities": [{"type": "Organization", "text": "Technology Ireland Company"}]}, {"text": "Ireland Japan Chamber of Commerce\nRicoh", "location": [2251, 2290], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}]}, {"type": "residesIn", "sentence": "\" Pictured are (L - R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan Akira Oyama, Corporate Executive Vice President, Ricoh said the award reflects the \u02bbwealth of symbiotic economic opportunity that lies in Irish-Japanese relations'.", "score": 0.274832, "arguments": [{"text": "Akira Oyama", "location": [3211, 3222], "entities": [{"type": "Person", "text": "Akira Oyama"}]}, {"text": "Japan", "location": [3205, 3210], "entities": [{"type": "GeopoliticalEntity", "text": "Japanese", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "\" Pictured are (L - R) Paul Gilsenan, President of Ireland Japan Chamber of Commerce; Akira Oyama, Corporate Executive Vice President, Ricoh; and H.E. Paul Kavanagh, Ambassador of Ireland to Japan Akira Oyama, Corporate Executive Vice President, Ricoh said the award reflects the \u02bbwealth of symbiotic economic opportunity that lies in Irish-Japanese relations'.", "score": 0.897638, "arguments": [{"text": "Ricoh", "location": [3260, 3265], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}, {"text": "said", "location": [3266, 3270], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "agentOf", "sentence": "Corporate Social Responsibility Ricoh Ireland said in 2017, it donated \u20a0175,000 worth of \u02bbmanaged document services technology' to Temple Street Children's Hospital and \u20a030,000 worth of collaborative technologies to FoodCloud, the platform that allows businesses to donate unsold fresh food produce to local charities.", "score": 0.968692, "arguments": [{"text": "Corporate Social Responsibility\nRicoh Ireland", "location": [3875, 3920], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}, {"text": "said", "location": [3921, 3925], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "partOf", "sentence": "\"Since the 1980s Ricoh Ireland has gone from strength to strength and as it grows, so too does the local team's impact on the Irish economy\u2026 Ricoh Ireland is a great success story for us - on both sides of the globe - and we will continue to invest in our Irish team as the market grows.", "score": 0.6669, "arguments": [{"text": "Ireland", "location": [3399, 3406], "entities": [{"type": "GeopoliticalEntity", "text": "Ireland Japan", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "Ricoh", "location": [3393, 3398], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}]}, {"type": "basedIn", "sentence": "\"Since the 1980s Ricoh Ireland has gone from strength to strength and as it grows, so too does the local team's impact on the Irish economy\u2026 Ricoh Ireland is a great success story for us - on both sides of the globe - and we will continue to invest in our Irish team as the market grows.", "score": 0.458384, "arguments": [{"text": "team", "location": [3638, 3642], "entities": [{"type": "Organization", "text": "team", "disambiguation": {"subtype": ["Sports"]}}]}, {"text": "Irish", "location": [3632, 3637], "entities": [{"type": "GeopoliticalEntity", "text": "Irish", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "\" In February 2017, the company opened its new Irish HQ in Dublin on the back of a \u20a06.5m investment, and the company hopes to double its workforce to 190 by 2020 and increase revenues to \u20a032m in the same period.", "score": 0.872001, "arguments": [{"text": "workforce", "location": [3800, 3809], "entities": [{"type": "Person", "text": "workforce"}]}, {"text": "its", "location": [3796, 3799], "entities": [{"type": "Organization", "text": "Corporate Social Responsibility\nRicoh Ireland"}]}]}, {"type": "timeOf", "sentence": "Corporate Social Responsibility Ricoh Ireland said in 2017, it donated \u20a0175,000 worth of \u02bbmanaged document services technology' to Temple Street Children's Hospital and \u20a030,000 worth of collaborative technologies to FoodCloud, the platform that allows businesses to donate unsold fresh food produce to local charities.", "score": 0.969422, "arguments": [{"text": "2017", "location": [3929, 3933], "entities": [{"type": "Date", "text": "2017"}]}, {"text": "said", "location": [3921, 3925], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "employedBy", "sentence": "Previous winners of the Ireland Japan Business Awards include Fujitsu Laboratories, SMBC, Takeda Pharmaceutical and Corvil.", "score": 0.598781, "arguments": [{"text": "winners", "location": [4326, 4333], "entities": [{"type": "Person", "text": "winners"}]}, {"text": "Business Awards", "location": [4355, 4370], "entities": [{"type": "Organization", "text": "Ireland Japan Business Awards"}]}]}, {"type": "partOf", "sentence": "Previous winners of the Ireland Japan Business Awards include Fujitsu Laboratories, SMBC, Takeda Pharmaceutical and Corvil.", "score": 0.988537, "arguments": [{"text": "Business Awards", "location": [4355, 4370], "entities": [{"type": "Organization", "text": "Ireland Japan Business Awards"}]}, {"text": "Ireland Japan", "location": [4341, 4354], "entities": [{"type": "GeopoliticalEntity", "text": "Ireland Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "Informing, illuminating and intelligent debate LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo Irish tech company LearnUpon has been named Technology Ireland Company of the Year, while Ricoh also won Company of the Year at the Ireland Japan Business Awards.", "score": 0.491806, "arguments": [{"text": "Company", "location": [241, 248], "entities": [{"type": "Organization", "text": "Technology Ireland Company"}]}, {"text": "Ireland Japan Business Awards", "location": [268, 297], "entities": [{"type": "Organization", "text": "Ireland Japan Business Awards"}]}]}, {"type": "partOf", "sentence": "Technology Ireland Industry Awards LearnUpon was named Company of the Year at the 26th Annual Technology Ireland Industry Awards on Friday 23 November 2018, in the Round Room of the Mansion House, Dublin.", "score": 0.783204, "arguments": [{"text": "Company", "location": [354, 361], "entities": [{"type": "Organization", "text": "Technology Ireland Company"}]}, {"text": "Annual Technology Ireland Industry Awards", "location": [386, 427], "entities": [{"type": "Organization", "text": "Annual Technology Ireland Industry Awards"}]}]}, {"type": "locatedAt", "sentence": "Technology Ireland Industry Awards LearnUpon was named Company of the Year at the 26th Annual Technology Ireland Industry Awards on Friday 23 November 2018, in the Round Room of the Mansion House, Dublin.", "score": 0.494188, "arguments": [{"text": "Annual Technology Ireland Industry Awards", "location": [386, 427], "entities": [{"type": "Organization", "text": "Annual Technology Ireland Industry Awards"}]}, {"text": "Round Room", "location": [463, 473], "entities": [{"type": "Facility", "text": "Round Room"}]}]}, {"type": "locatedAt", "sentence": "Technology Ireland Industry Awards LearnUpon was named Company of the Year at the 26th Annual Technology Ireland Industry Awards on Friday 23 November 2018, in the Round Room of the Mansion House, Dublin.", "score": 0.78321, "arguments": [{"text": "Round Room", "location": [463, 473], "entities": [{"type": "Facility", "text": "Round Room"}]}, {"text": "Mansion House", "location": [481, 494], "entities": [{"type": "Facility", "text": "Mansion House"}]}]}, {"type": "locatedAt", "sentence": "Technology Ireland Industry Awards LearnUpon was named Company of the Year at the 26th Annual Technology Ireland Industry Awards on Friday 23 November 2018, in the Round Room of the Mansion House, Dublin.", "score": 0.586992, "arguments": [{"text": "Round Room", "location": [463, 473], "entities": [{"type": "Facility", "text": "Round Room"}]}, {"text": "Dublin", "location": [496, 502], "entities": [{"type": "GeopoliticalEntity", "text": "Irish HQ"}]}]}], "keywords": [{"text": "Technology Ireland Company of the Year", "sentiment": {"score": 0.912072, "label": "positive"}, "relevance": 0.855187, "count": 2}, {"text": "companies of the year", "sentiment": {"score": 0.827604, "label": "positive"}, "relevance": 0.763223, "count": 1}, {"text": "Ireland Japan Business Awards", "sentiment": {"score": 0.827604, "label": "positive"}, "relevance": 0.701497, "count": 2}, {"text": "Irish tech company LearnUpon", "sentiment": {"score": 0.827604, "label": "positive"}, "relevance": 0.660358, "count": 1}, {"text": "Ricoh", "sentiment": {"score": 0.874108, "label": "positive"}, "relevance": 0.653947, "count": 7}, {"text": "intelligent debate LearnUpon", "sentiment": {"score": 0.827604, "label": "positive"}, "relevance": 0.608874, "count": 1}, {"text": "Technology Ireland", "sentiment": {"score": 0.596726, "label": "positive"}, "relevance": 0.588043, "count": 1}, {"text": "Technology Ireland Director Una Fitzpatrick", "sentiment": {"score": 0.596726, "label": "positive"}, "relevance": 0.561681, "count": 1}, {"text": "Corporate Executive Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.557721, "count": 2}, {"text": "Outstanding Achievement", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.556445, "count": 1}, {"text": "Company of the Year", "sentiment": {"score": 0.912072, "label": "positive"}, "relevance": 0.553718, "count": 5}, {"text": "Ireland Japan Chamber", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.546226, "count": 1}, {"text": "Technology Ireland Person of the Year", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.546151, "count": 2}, {"text": "Akira Oyama", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544851, "count": 1}, {"text": "Award", "sentiment": {"score": 0.596726, "label": "positive"}, "relevance": 0.543365, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542606, "count": 3}, {"text": "Irish economy", "sentiment": {"score": 0.97954, "label": "positive"}, "relevance": 0.541924, "count": 1}, {"text": "Ricoh Ireland", "sentiment": {"score": 0.901489, "label": "positive"}, "relevance": 0.540115, "count": 4}, {"text": "Ireland Japan Chamber of Commerce", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537644, "count": 1}, {"text": "award winners", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.537531, "count": 1}, {"text": "President of Ireland Japan Chamber of Commerce", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535245, "count": 1}, {"text": "Irish graduates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535051, "count": 1}, {"text": "Technology", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.534224, "count": 1}, {"text": "market today", "sentiment": {"score": 0.596726, "label": "positive"}, "relevance": 0.532915, "count": 1}, {"text": "Fidelity Investments Ireland", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.53118, "count": 2}, {"text": "Coolest Projects", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.530701, "count": 1}, {"text": "Noel King", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.530317, "count": 1}, {"text": "annual awards", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529352, "count": 1}, {"text": "Irish team", "sentiment": {"score": 0.97954, "label": "positive"}, "relevance": 0.528885, "count": 1}, {"text": "event", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528025, "count": 1}, {"text": "Phil Keoghan", "sentiment": {"score": 0.722467, "label": "positive"}, "relevance": 0.5277, "count": 1}, {"text": "Talent Development", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.527162, "count": 1}, {"text": "Digital Technology Services Project of the Year", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.526406, "count": 1}, {"text": "team", "sentiment": {"score": 0.722467, "label": "positive"}, "relevance": 0.523836, "count": 1}, {"text": "founder", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.522524, "count": 1}, {"text": "outstanding contributions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522159, "count": 1}, {"text": "increase revenues", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521935, "count": 1}, {"text": "Ricoh\u2019s relationship", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521601, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521342, "count": 1}, {"text": "Dublin", "sentiment": {"score": 0.827604, "label": "positive"}, "relevance": 0.52125, "count": 4}, {"text": "Ireland", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519852, "count": 1}, {"text": "Siren", "sentiment": {"score": 0.982313, "label": "positive"}, "relevance": 0.519684, "count": 2}, {"text": "award", "sentiment": {"score": 0.722467, "label": "positive"}, "relevance": 0.518623, "count": 2}, {"text": "platform", "sentiment": {"score": 0.923554, "label": "positive"}, "relevance": 0.517622, "count": 3}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517582, "count": 2}, {"text": "Japan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517453, "count": 1}, {"text": "strength", "sentiment": {"score": 0.97954, "label": "positive"}, "relevance": 0.517161, "count": 2}, {"text": "technology", "sentiment": {"score": 0.954812, "label": "positive"}, "relevance": 0.517132, "count": 1}, {"text": "platinum sponsors Vhi Healthcare", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516377, "count": 1}, {"text": "investment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515372, "count": 1}]}, "extracted_metadata": {"sha1": "7a605dac9054393e501cdfb07c20568c417fcca7", "filename": "1543041238688.zip-0227df4504c0cf588049087d20826d0c.xml", "file_type": "json"}, "title": "LearnUpon & Ricoh named companies of the year in separate ceremonies in Dublin and Tokyo", "forum_title": "Inside Ireland"}]}